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Abstract
Helicobacter pylori (H. pylori), a bacterium that is present in the stomach of half of the
world’s population with disproportionate burden in developing countries, is the strongest known
biological risk factor for gastric cancer. Gastric cancer is the fourth most common type of cancer
and the second cause of cancer death in the world. In particular, in Mexico gastric cancer is the
third highest cause of cancer death in adults, with some regions having cancer mortality rates
that are twice the national average (8.0 vs. 3.9 per 100,000, respectively). H. pylori can be
treated with antibiotics, but widespread treatment may lead to significant levels of antibiotic
resistance (ABR). ABR is one of the main causes of H. pylori treatment failure and represents
one of the greatest emerging global health threats.
In this thesis, we use statistical and mathematical modeling to investigate the health benefits,
harms, costs and cost-effectiveness of screen-and-treat strategies for identifying and treating
persons with H. pylori to inform public health practice in three steps. First, we estimated the
age-specific force of infection of H. pylori –defined as the instantaneous per capita rate at which
susceptibles acquire infection– using a novel hierarchical nonlinear Bayesian catalytic epidemic
model with data from a national H. pylori seroepidemiology survey in Mexico.
Second, we developed an age-structured, susceptible-infected-susceptible (SIS) transmis-
sion model of H. pylori infection in Mexico that included both treatment-sensitive and treatment-
resistant strains. Model parameters were derived from the published literature and estimated
from primary data. Using the model, we projected H. pylori infection and resistance levels
over 20 years without treatment and for three hypothetical population-wide treatment policies
assumed to be implemented in 2018. In sensitivity analyses, we considered different mixing
patterns and trends of background antibiotic use. We validated the model against historical
values of prevalence of infection and ABR of H. pylori.
Third, we expanded the SIS model to incorporate the natural history of gastric carcinogene-
sis including gastritis, intestinal metaplasia, dysplasia and ultimately non-cardia gastric cancer.
We then estimated the cost-effectiveness of various screen-and-treat strategies for H. pylori in-
fection and ABR in the Mexican population from the health sector perspective.
iv
Contents
Acknowledgements i
Dedication iii
Abstract iv
List of Tables viii
List of Figures ix
1 Introduction 1
2 Force of infection ofHelicobacter pylori in Mexico: Evidence from a national survey
using a hierarchical Bayesian model 5
2.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
2.2 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
2.2.1 Force of infection as a catalytic model . . . . . . . . . . . . . . . . . . 6
2.2.2 Seroprevalence of H. pylori in Mexico . . . . . . . . . . . . . . . . . . 8
2.2.3 Functional form of catalytic model of H. pylori infection in Mexico . . 8
2.2.4 Statistical estimation of the force of infection of H. pylori infection . . 11
2.2.5 Hierarchical nonlinear Bayesian model . . . . . . . . . . . . . . . . . 11
2.2.6 Model validation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
2.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
2.3.1 Force of infection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
2.3.2 Model validation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
v
2.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
3 Modeling the impact of antibiotic consumption on the epidemiology of Helicobacter
pylori in the presence of antibiotic resistance 21
3.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
3.1.1 H. pylori . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
3.1.2 Antibiotic treatment and resistance . . . . . . . . . . . . . . . . . . . . 22
3.2 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
3.2.1 The epidemiologic model . . . . . . . . . . . . . . . . . . . . . . . . 23
3.2.2 Resistance model . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
3.2.3 Parameters . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
3.2.4 Antibiotic treatment policies . . . . . . . . . . . . . . . . . . . . . . . 34
3.2.5 Epidemiologic outcomes . . . . . . . . . . . . . . . . . . . . . . . . . 34
3.2.6 Model validation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
3.2.7 Cohort effects . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
3.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
3.3.1 Estimates of WAIFW matrices and transmission parameters . . . . . . 40
3.3.2 FOI with estimated WAIFW matrices . . . . . . . . . . . . . . . . . . 44
3.3.3 Validation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
3.3.4 Impact of different antibiotic mass-treatment policies on epidemiologic
outcomes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49
3.3.5 Cohort effects of different antibiotic mass-treatment policies . . . . . . 50
3.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
4 Cost-effectiveness analysis of population screening and treatment of Helicobacter
pylori in the setting of antibiotic resistance 55
4.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55
4.2 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58
4.2.1 Mathematical model . . . . . . . . . . . . . . . . . . . . . . . . . . . 58
4.2.2 Calibration of gastric disease dynamics . . . . . . . . . . . . . . . . . 62
4.2.3 Screen-and-treat algorithms . . . . . . . . . . . . . . . . . . . . . . . 73
4.2.4 Screen-and-treat policies . . . . . . . . . . . . . . . . . . . . . . . . . 74
4.2.5 Variables and Parameters . . . . . . . . . . . . . . . . . . . . . . . . . 74
vi
4.2.6 Epidemiologic impact of screen-and-treat strategies . . . . . . . . . . . 78
4.2.7 Costs of screen-and-treat strategies . . . . . . . . . . . . . . . . . . . 80
4.2.8 Methodological assumptions . . . . . . . . . . . . . . . . . . . . . . . 82
4.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82
4.3.1 Model fit . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82
4.3.2 Cost-effectiveness analysis . . . . . . . . . . . . . . . . . . . . . . . . 85
4.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 86
5 Conclusion and discussion 90
5.1 Implications . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 91
5.2 Future work . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92
5.3 Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92
Bibliography 93
Appendix A. Demographic model 119
A.1 Demographic model structure . . . . . . . . . . . . . . . . . . . . . . . . . . . 119
Appendix B. Additional Figures 121
B.1 H. pylori SIS model in the setting of antibiotic resistance . . . . . . . . . . . . 122
B.2 Cost-effectiveness analysis of population screening and treatment of H. pylori
in the setting of antibiotic resistance . . . . . . . . . . . . . . . . . . . . . . . 123
Appendix C. Glossary and Acronyms 124
C.1 Glossary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 124
C.2 Acronyms . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 127
vii
List of Tables
2.1 Posterior mean estimates, SD, and lower and upper bounds of the 95% credi-
ble interval of the national-level asymptote and rate parameters of the catalytic
epidemic model, average age at infection and average age at infection of those
eventually infected . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
3.1 Four different WAIFW matrix structures . . . . . . . . . . . . . . . . . . . . . 27
3.2 Description of variables, subscripts and superscripts . . . . . . . . . . . . . . . 31
3.3 Description of parameters . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
3.4 Point estimates and standard errors in parentheses of the β transmission param-
eters for different WAIFW matrices for H. pylori in Mexico. . . . . . . . . . . 42
3.5 Point estimates and standard errors in parentheses of the β transmission param-
eters for different WAIFW matrices for the state of Morelos, Mexico. . . . . . . 44
4.1 Contrasting Bayes theorem with a calibration process. . . . . . . . . . . . . . . 63
4.2 Gastric lesions by age and H. pylori status for a sample of patients in Mexico in
1999-2002. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66
4.3 Gastric cancer incidence in Mexico in 2012 by age group with corresponding
standard errors (SE), and 95% CI lower bounds (LB) and upper bounds (UB).
Rates per 100,000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68
4.4 Estimated coefficients of the multinomial model. . . . . . . . . . . . . . . . . 71
4.5 Description of variables, subscripts and superscripts . . . . . . . . . . . . . . . 75
4.6 Description of parameters . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76
4.7 Cost-effectiveness analysis of screen-and-treat strategies for H. pylori infection
in the setting of antibiotic resistance. D: strongly dominated strategy; d: weakly
dominated strategy. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 86
C.1 Acronyms . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 127
viii
List of Figures
2.1 Observed prevalence of H. pylori in Mexico by state in 1987-88 with 95% CI . 9
2.2 Empirical prevalence of H. pylori in Mexico by age nationally and in three
different states. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
2.3 Empirical prevalence of H. pylori in Mexico by age in four different states with
different amount of data, together with model-predicted prevalence using NLS.
The upper two reflect states with data for all ages and the lower two reflect states
with limited amount of data for some ages. . . . . . . . . . . . . . . . . . . . . 12
2.4 State-specific posterior mean and 95% credible interval for the asymptote and
rate parameters. Solid and dashed vertical lines represent the national-level
posterior mean and 95% credible interval, respectively. . . . . . . . . . . . . . 15
2.5 Model fit to the national prevalence of H. pylori by age in Mexico in 1987-88.
Gray circles denote empirical prevalence with size proportional to sample size,
and 95% confidence interval per 1-year age group. The red solid line denotes
the model-predicted posterior mean and the red dashed lines denote the 95%
credible bounds. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
2.6 Model fit to the state-specific prevalence of H. pylori by age in Mexico in 1987-
88. Gray circles denote empirical prevalence with size proportional to sam-
ple size, and 95% confidence interval. The red solid line denotes the model-
predicted posterior mean and the red dashed lines denote the 95% credible bounds. 17
2.7 Model-predicted national force of infection of H. pylori by age in Mexico in
1987-88. The solid line denotes the model-predicted posterior mean and the
dashed lines denote the 95% credible bounds. . . . . . . . . . . . . . . . . . . 18
ix
2.8 Model-predicted state-specific force of infection of H. pylori by age in Mexico
in 1987-88. The solid line denotes the model-predicted posterior mean and the
dashed lines denote the 95% credible bounds. . . . . . . . . . . . . . . . . . . 19
3.1 Simplified diagram of a SI model describing the transmission dynamics of H.
pylori. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
3.2 SIS model of antibiotic therapy and infection incorporating drug-sensitive and
resistant strains. Ir = I0r+I1r and primes denote parameters for resistant strains,
α is the prescribing rate (per unit time), 1/γ the average length of treatment
(typically days) and 1/f the average duration of infection (typically months or
years). Antibiotic treatment is assumed to either clear sensitive strains or induce
acquired resistance with probability σ. . . . . . . . . . . . . . . . . . . . . . . 30
3.3 Average consumption rate of clarithromycin over time in Mexico . . . . . . . . 37
3.4 Relative rate of antibiotic consumption of clarithromycin by age group . . . . . 38
3.5 Comparison of observed seroprevalence of H. pylori infection by age among
adolescents in the state of Morelos, Mexico in 1987–88 and 1999 with the
prevalence predicted for the state of Morelos with the catalytic model of Chap-
ter 2. Dotted lines represent the 95%CR of the prevalence predicted by the
catalytic model. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
3.6 Perspective plots of the WAIFW matrices for H. pylori infection in Mexico. . . 41
3.7 Correlations between the β parameters of different WAIFW matrices. . . . . . 43
3.8 Comparison of the piecewise FOI of H. pylori predicted with each of the national-
level WAIFW matrices using Equation (2.1) to the continuous FOI estimated in
Mexico in 1987-88 with the catalytic model in Chapter 2. . . . . . . . . . . . . 45
3.9 Comparison of the piecewise FOI of H. pylori predicted with each of the Morelos-
specific WAIFW matrices using Equation (2.1) to the continuous FOI estimated
in the state of Morelos, Mexico in 1987-88 with the catalytic model in Chapter 2. 46
3.10 Comparison of observed age-specific prevalence of H. pylori in Mexico in 1987-
88 with the age-specific prevalence predicted with the SI model. . . . . . . . . 47
3.11 Comparison of model-predicted prevalence of H. pylori between 1988 and 1999,
and observed prevalence with 95% CI in 1988 and 1999 in the state of Morelos,
Mexico in adolescents age 11-24 years old. . . . . . . . . . . . . . . . . . . . 48
x
3.12 Mean and 95% model-predicted CI of prevalence of clarithromycin-resistant H.
pylori in Mexico between 1988 and 1999, and observed prevalence resistance in
Mexico City. Confidence intervals of observed resistance were computed using
the Binomial exact method. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49
3.13 Impact of different antibiotic treatment policies on prevalence of H. pylori in-
fection and resistance for different antibiotic mass-treatment policies. . . . . . 50
3.14 Cohort effects of different antibiotic mass-treatment policies on prevalence of
H. pylori infection. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51
3.15 Cohort effects of different antibiotic mass-treatment policies on prevalence of
resistance. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
4.1 SIS model of screen-and-treat with antibiotic therapy incorporating drug-sensitive
and resistant strains for each gastric disease state g ∈ {N,G,A,M,D,NCGC}.
Primes denote parameters for resistant strains. Parameters in red refer to screen-
ing parameters and those in blue refer to susceptibility test. . . . . . . . . . . . 60
4.2 Diagram of gastric disease dynamics . . . . . . . . . . . . . . . . . . . . . . . 62
4.3 Prevalence of gastric lesions by age . . . . . . . . . . . . . . . . . . . . . . . 65
4.4 Proportion of gastric lesions by age and H. pylori status for a sample in Mexico
in 1999-2002 with multinomial confidence intervals. . . . . . . . . . . . . . . 67
4.5 Gastric cancer incidence in Mexico in 2012 by age group with confidence inter-
vals, and crude and age-standardized rates (ASR). . . . . . . . . . . . . . . . 69
4.6 Predicted proportion of gastric lesions by age and H. pylori status with 95% CI
error bands from a sample of patients in Mexico in 1999-2002. . . . . . . . . . 71
4.7 Difference in predicted proportion of gastric lesions by age and H. pylori status
with 95% CI error bands from a sample of patients in Mexico in 1999-2002. . . 72
4.8 Observed and model-predicted prevalence of gastritis using MAP estimate. . . 83
4.9 Observed and model-predicted proportions of gastric lesions by age and H. py-
lori infection status using MAP estimate for the population in Mexico . . . . . 84
4.10 Observed and model-predicted gastric cancer incidence using MAP estimate for
the population in Mexico. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85
4.11 Cost-effectiveness frontier (represented by the solid line) . . . . . . . . . . . . 87
xi
B.1 Impact of different antibiotic treatment policies on prevalence of H. pylori in-
fection and resistance for different antibiotic mass-treatment policies under dif-
ferent WAIFW matrices and background antibiotic uptakes. . . . . . . . . . . . 122
B.2 Screen and treat algorithm for individuals in all infectious disease states . . . . 123
xii
Chapter 1
Introduction
Helicobacter pylori (H. pylori ), a gram-negative microaerophilic bacterium that is present in the
stomach of half of the world’s population with disproportionate burden in developing countries,
is the strongest known biological risk factor for gastric cancer.[1, 2] Gastric cancer is the fourth
most common type of cancer and the second leading cause of cancer death in the world, with
almost 70% of cases occurring in developing countries. Gastric cancer is associated with poor
survival and reduced quality of life, as a high percentage of gastric cancer cases are detected at
a late stage. Latin America has the second highest rate of gastric cancer mortality in the world.
In particular, in Mexico gastric cancer is the third highest cause of cancer death in adults, with
some regions having cancer mortality rates that are twice the national average (8.0 vs. 3.9 per
100,000, respectively).[3] Therefore, gastric cancer represents a major public health problem in
regions with high prevalence of H. pylori
The mode of transmission of H. pylori remains unclear. Transmission is believed to occur
through close personal contact, such as oral-oral or fecal-oral, particularly within the family and
typically in early childhood.[1, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16] Once infected with H.
pylori, individuals will experience life-long infection in the absence of antibiotic treatment.[17,
18]
The force of infection is the instantaneous rate at which susceptible individuals acquire
infection. It is an important epidemiological quantity and a key parameter for mathematical
models of disease transmission, which are used to estimate disease burden and the effectiveness
and cost-effectiveness of infectious disease treatment and prevention.[19, 20, 21] Like many
infectious diseases, it is infeasible to directly measure the force of infection of H. pylori.[22,
1
223, 24]
H. pylori infection can be cleared with antibiotics, which in theory can reduce the risk of
gastric cancer, duodenal and gastric ulcers, but previously infected individuals are at risk of
reinfection.[25, 26] In addition, antibiotic treatment can result in antibiotic resistance (ABR),
which is the natural response of bacteria to resist the threats designed to eliminate them. Non-
adherence and ABR are the main causes of H. pylori treatment failure.[26, 27, 28, 29, 30, 31]
ABR reduces the effectiveness of treatment and represents one of the greatest emerging global
health threats.[32, 33, 34] Resistant strains of H. pylori have been identified in Latin American
to most antibiotics typically used to treat it.[35]
Given the high burden of H. pylori infection in the population, the idea of antibiotic-based
mass eradication in developing regions has been suggested, and even implemented in targeted
high-risk populations.[36] However, the modest benefits of H. pylori mass eradication programs
may be outweighed by the development of treatment-induced ABR. Therefore, it is important
to only treat appropriate cases with selected regimens based on the observed patterns of ABR
in the target population. Under a "screen-and-treat" approach asymptomatic individuals (i.e.,
individuals without symptoms of having the disease of interest) are subjected to a screening test
and treatment decisions are based on the test result, which should be provided soon or, ideally,
immediately after a positive screening test.[37]
In this thesis, we address these issues across three different chapters.
In Chapter 2, we showed that under certain assumptions the age-specific force of infection
of H. pylori can be estimated from national seroprevalence data. Specifically, we estimated the
age-specific force of H. pylori infection in Mexico (a middle-income country with a high preva-
lence of infection). We used data from a nationally representative seroepidemiology survey
conducted in Mexico prior to widespread antibiotic treatment of H. pylori with rich geograph-
ical variation. Given the large heterogeneity in the number of samples obtained in each state,
we used a nonlinear Bayesian hierarchical catalytic model that allows us to estimate the force
of infection in each state in Mexico while simultaneously estimating the national average force
of infection. We demonstrate that this method dramatically stabilizes estimation by shrinking
the state-specific force of infection toward the national estimate, particularly on states with low
data.
We modeled the number of individuals with H. pylori at a given age in each state as a
binomial random variable. We assumed that the cumulative risk of infection by a given age
3follows a modified exponential distribution, allowing some fraction of the population to remain
uninfected. The cumulative risk of infection was modeled for each state in Mexico and these
state-specific cumulative risk curves were shrunk toward the overall national cumulative risk
curve using Bayesian hierarchical models. These parameters were used to estimate the force
of infection by age in each Mexican state. Models were estimated using Markov chain Monte
Carlo (MCMC) methods.
We found that national H. pylori prevalence estimates plateau at 86.1% [95% credible inter-
val (CR): 84.2%-88.2%]. The rate of increase of prevalence per year of age is 0.093 [95%CR:
0.084-0.103]. We estimated an average age at infection of the population eventually infected
of 12.5 [95%CR: 11.3-13.8] and the age-specific force of infection was highest at birth 0.080
[95%CR: 0.089-0.071] and decreased to zero with increasing age.
This chapter presents the first estimation of the force of infection of H. pylori using seroepi-
demiologic data.
In Chapter 3, we developed an age-structured, susceptible-infected-susceptible (SIS) trans-
mission model of H. pylori infection in Mexico that included both treatment-sensitive and
treatment-resistant strains. Antibiotic treatment was assumed to either clear sensitive strains
or induce acquired resistance (and had no effect on resistant strains). In addition, the model
included the effects of both background antibiotic use and antibiotic treatment specifically in-
tended to treat H. pylori infection. Model parameters were derived from the published lit-
erature and estimated from primary data. Using the model, we projected H. pylori infection
and resistance levels over 20 years without treatment and for three hypothetical population-
wide treatment policies assumed to be implemented in 2018: (1) treat children only (2-6 year-
olds); (2) treat older adults only (>40 years old); (3) treat everyone regardless of age. Clar-
ithromycin—introduced in Mexico in 1991—was the antibiotic considered for the treatment
policies. In sensitivity analyses, we considered different mixing patterns and trends of back-
ground antibiotic use. We validated the model against historical values of prevalence of infec-
tion and ABR of H. pylori.
We found that in the absence of a mass-treatment policy, our model predicts infection begins
to rise in 2022, mostly caused by treatment-induced resistant strains as a product of background
use of antibiotics. The impact of the policies is immediate on decreasing infection but also
increasing ABR. For example, policy 3 decreases infection by 21% but increases ABR by 57%
after the first year of implementation. The relative size of the decrease in infection vs. the
4increase in ABR for policy 3 is 37%. These results were robust across all scenarios considered
in sensitivity analyses.
In summary, mass-treatment policies have a greater effect on increasing ABR, allowing
resistant strains take over infection. Given the high proportion of ABR at the time of the policy
implementation, mass treatment strategies are not recommended for Mexico.
In Chapter 4, we conducted a cost-effectiveness analysis (CEA) to compare the costs, life
years and quality-adjusted life years (QALYs) of different screen-and-treat strategies for H.
pylori infection and ABR in the Mexican population from the health sector perspective. We
considered different testing strategies including those used to identify ABR strains.
We expanded the SIS model from Chapter 3 to incorporate the natural history of gastric car-
cinogenesis including gastritis, intestinal metaplasia, dysplasia and ultimately non-cardia gastric
cancer. We calibrated the parameters describing gastric disease dynamics using a Bayesian ap-
proach. We then implemented alternative screen-and-treat strategies with two different testing
algorithms: (1) test only for H. pylori infection and treat if positive, and (2) test for H. pylori
infection and if positive, test for susceptibility to clarithromycin.
All screening policies produced higher effectiveness compared to a no-screen-and-no-treat
policy. However, all policies were costlier compared to a do-nothing strategy. Using a cost-
effectiveness threshold of the GDP per capita (MXN$132,000 in Mexico), we found screening
and treating for H. pylori all the population would be considered cost-effective.
Chapter 2
Force of infection of Helicobacter pylori
in Mexico: Evidence from a national
survey using a hierarchical Bayesian
model
2.1 Introduction
H. pylori is one of the most prevalent global pathogens, the strongest known biological risk
factor for gastric cancer (about a six-fold increase of risk) and is responsible for approximately
80% of gastric ulcers.[1, 2, 38, 39] Gastric cancer is the fourth most common type of cancer
and the second cause of cancer death globally.[40] H. pylori is a gram-negative, microaerophilic
bacterium commonly found in the epithelial lining of the human stomach.[41]
The mode of transmission of H. pylori remains unclear. Transmission appears to occur
through close personal contact, such as oral-oral or fecal-oral, particularly within the family and
typically in early childhood.[1, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16] Once infected with H.
pylori, individuals will experience life-long infection in the absence of antibiotic treatment.[17,
18] The global burden of disease is substantial, with H. pylori present in the stomach of half
of the world’s population; however, H. pylori most heavily burdens low- and middle-income
countries (LMICs) where the proportion of people infected is approximately 70%.[42, 43, 44]
5
6For example, a prevalence study in Mexico showed that 66% of the Mexican population was
infected with H. pylori and that this prevalence increases with age, reaching up to 80% in adults
25 years old and older.[45] However, this study also found significant variation in prevalence
by age, socioeconomic status and geography (e.g., state-level prevalence ranged from 48% to
85%).
The force of infection is the instantaneous rate at which susceptible individuals acquire
infection. It is an important epidemiological quantity and a key parameter for mathematical
models of disease transmission, which are used to estimate disease burden and the effective-
ness and cost-effectiveness of infectious disease treatment and prevention.[19, 20, 21] Like
many infectious diseases, it is infeasible to directly measure the force of infection of H. py-
lori.[22, 23, 24] However, under certain assumptions, it can be estimated using population-level
seroprevalence data.[19, 46, 47, 48] Despite the existence of seroprevalence data of H. pylori
its force of infection has not been previously estimated.
In this paper, we show how the age-specific force of infection of H. pylori can be estimated
from national seroprevalence data. The purpose of this paper is to estimate the age-specific force
of H. pylori infection in Mexico (a middle-income country with a high prevalence of infection).
We used data from a nationally representative seroepidemiology survey conducted in Mexico
prior to widespread antibiotic treatment of H. pylori with rich geographical variation. Given
the large heterogeneity in the number of samples obtained in each state, we used a nonlinear
Bayesian hierarchical catalytic model that allows us to estimate the force of infection in each
state in Mexico while simultaneously estimating the national average force of infection. We
demonstrate that this method dramatically stabilizes estimation by shrinking the state-specific
force of infection toward the national estimate, particularly on states with low data.
2.2 Methods
2.2.1 Force of infection as a catalytic model
The force of infection is the key quantity governing disease transmission within a given popula-
tion and is defined as the instantaneous per capita rate at which susceptible individuals acquire
infection (i.e., the hazard of infection). It reflects both the degree of contact between suscepti-
ble and infected individuals and the transmissibility of the pathogen per contact. In cases where
contact is age dependent, the force of infection is itself a function of age analogous to the hazard
7rate being a function of time in a survival model.[46]
Formally, let P (a) denote the probability that an individual susceptible at birth is still sus-
ceptible at age a; this is identical to the cumulative survival function in a survival analysis. Let
λ(a) denote the force of infection at age a, which represents the rate of infection of the suscep-
tible population P (a). In terms of a survival model, the force of infection λ(a) represents the
instantaneous infection hazard rate. Therefore, for lifelong infections (or infections conferring
lifelong immunity) that do not significantly affect mortality, λ(a) can be defined as
λ(a) = − 1
P (a)
dP (a)
da
, (2.1)
under the assumption that the population is in dynamic equilibrium (meaning that P (a) is con-
stant over time and not changing generation to generation).
Equation (2.1) specifies a so-called catalytic epidemic model, first defined by Muench.[48]
The term catalytic model derives from its origins in chemistry, where these models were used to
study chemical reaction kinetics. Catalytic epidemic models have been widely used to estimate
the force of infection of different infectious disease such as measles, rubella, mumps, hepatitis A
and yellow fever using seroprevalence epidemiological data from settings where these diseases
do not significantly affect mortality.[19]
Catalytic models can easily be written in terms of the cumulative probability of infection
by age a, F (a) = 1 − P (a), which more directly corresponds to how seroprevalence data is
collected.[46, 48] In terms of F (a), the force of infection, λ(a), becomes:
λ(a) = 11− F (a)
dF (a)
da
. (2.2)
Note that rearranging Equation (2.2) we can solve for F (a) as a function of λ(a), which
is equivalent to a survival model where the probability of infection by age a is the cumulative
distribution function of the time to infection:
F (a) = 1− exp
[
−
∫ a
0
λ(s)ds
]
. (2.3)
Further, it is possible to estimate the average age of infection, A, which is equivalent to the
average time spent in the susceptible group before becoming infected:
A =
∫ L
0
(1− F (a))da, (2.4)
8where L is the life expectancy of the population of interest. The average age, A at infection is a
parameter of considerable epidemiological significance for H. pylori since low values of A are
associated with high infectivity during childhood.[49] A could be a useful summary measure
of the FOI to easily compare across settings (e.g., across states and countries). And also, could
have policy implications like deciding optimal age of screening or treatment.
It is possible that some individuals never end up infected over their lifetimes. If this is the
case, A is a combination of the average age at infection of individuals who eventually become
infected, Ae, and life expectancy, L, for those who are never infected. Ae can be calculated
as[46]
Ae =
A− L(1− α)
α
, (2.5)
where α is the proportion of the population who ultimately becomes infected. The difference
betweenA andAe decreases as the proportion of the population eventually infected α increases.
2.2.2 Seroprevalence of H. pylori in Mexico
In 1987-1988, the National Seroepidemiological Survey (NSS) was conducted in Mexico as
a nationally representative survey of H. pylori infection.[45, 50] The survey was designed to
represent the country by including all 32 states of Mexico, all ages, all socioeconomic levels and
both sexes.[50] In total, 32,200 households were surveyed and more than 70,000 serum samples
were collected. Of these samples, 11,605 individuals were used for H. pylori testing and out
of these, 7,720 (66%) were seropositive for H. pylori. H. pylori infection was determined
by ELISA detection of IgG antibodies to specific H. pylori antigens. H. pylori prevalence in
Mexico varies by state and can be as low as 48% in the state of Chihuahua and as high as 83%
in the state of Baja California Sur, Figure 2.1.
2.2.3 Functional form of catalytic model of H. pylori infection in Mexico
The NSS data were collected prior to widespread antibiotic treatment of H. pylori so we can
assume that the prevalence of infection as a function of age is cumulative and that the population
is in steady state. The age-specific prevalence measured nationally and in three states is shown
in Figure 2.2 and it is clear that the trend is monotonically non-decreasing. Based on the shape
of these data, we assume that the state-specific cumulative probability of H. pylori infection,
9Figure 2.1: Observed prevalence of H. pylori in Mexico by state in 1987-88 with 95% CI
Fi(a), for each state i follow a constrained exponential functional form:
Fi(a) = αi(1− e−γia), (2.6)
where αi ≤ 1 is the state-specific proportion of the population who eventually becomes infected
and γi is the state-specific rate of infection among those who eventually become infected. We
allow α and γ to vary by state to reflect the heterogeneity in H. pylori prevalence trends resulting
from differences in socioeconomic and environmental factors. Note that for all states, we as-
sume that no children are infected at birth (Fi(0) = 0) since there is no biological evidence for
vertical transmission of H. pylori from mother to child during pregnancy, labor, or delivery.[51]
Based on this functional form for the cumulative probability of infection, we use equation
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Figure 2.2: Empirical prevalence of H. pylori in Mexico by age nationally and in three different
states.
(2.2) to solve for the state-specific force of infection, λi(a), in terms of αi and γi:
λi(a) =
αiγie
−γia
1− αi(1− e−γia) . (2.7)
Note that if the entire population is eventually infected in a given state (i.e., αi = 1),
λi(a) = γi and Equation (2.6) reduces to a traditional exponential model in survival analysis.
The average age at infection can be calculated from Equations (2.4) and (2.6) for each state i:
Ai =
L (1− αi) γi − e−γiL + 1
γi
, (2.8)
where life expectancy, L, is 70 years for Mexico in 1987-88 and assumed to be the same for all
states.[52]
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2.2.4 Statistical estimation of the force of infection of H. pylori infection
We used statistical methods to estimate the parameters α and γ that best fit the cumulative
probability of infection in each state and then calculated the corresponding force of infection.
Due to the high degree of variation in sample composition for each state in the NSS, traditional
nonlinear least-squares (NLS) estimation yielded imprecise, unstable, or unrealistic estimates
of the α and γ. This could translate into estimates of force of infection that are implausibly
high or low with wide confidence intervals when only a small number of people are sampled
(and, for instance, none are infected). For example, some states had individuals sampled at all
ages and while others had limited data for certain ages. In Figure 2.2 we show the empirical
prevalence in four different states with varying amounts of data and the predicted prevalence
for these states using NLS. Nuevo Leon and Mexico City have more data and more variability
in terms of disease status compared to the states of Baja California Sur and Morelos. The state
of Baja California Sur is a state where all adults sampled older than twenty years old (n=24)
are positive for H. pylori. The resulting parameter estimates are implausibly high based on our
current knowledge of H. pylori.
In order to solve these issues, we instead implemented a hierarchical Bayesian nonlinear
model that "borrows" information from all states when estimating state-specific effects. Such
models have been described in detail elsewhere [53] and are known to reduce mean squared
error of model estimates in some settings. We are unaware of these models having been applied
to catalytic models to estimate force of infection. We first use hierarchical Bayesian nonlinear
models to estimate the posterior distribution of the α and γ parameters of model (2.6) for each
of the 32 states. We then estimate the aggregated and state-specific force of infection of H.
pylori in Mexico.
2.2.5 Hierarchical nonlinear Bayesian model
We assume that for each state i = 1, . . . , 32 the number of infected individuals yi(a) at age
a follows a binomial distribution where ni(a) is the sample size and pi(a) is the cumulative
12
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Figure 2.3: Empirical prevalence of H. pylori in Mexico by age in four different states with
different amount of data, together with model-predicted prevalence using NLS. The upper two
reflect states with data for all ages and the lower two reflect states with limited amount of data
for some ages.
probability of infection (i.e., Fi(a)) in state i:
yi(a) ∼ Binomial (ni(a), pi(a)) ,
pi(a) = Fi(a) = αi
(
1− e−γia) ,αi
γi
 ∼MVN
α0
γ0
 ,Σ
 ,
Σ ∼ IW
103 0
0 103
 , 2
 ,
(2.9)
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Note that each of the 32 states has its own set of parameters αi and γi, but these state-specific
parameters "borrow" information from each other by assuming that they collectively follow a
multivariate Normal (MVN ) distribution centered at α0 and γ0, which can be interpreted as
the average total infection probability and infection rate for all of Mexico.
For the covariance matrix, we use an inverse Wishart (IW ) distribution of two degrees of
freedom. The IW is a widely-used prior distribution for covariance matrices; the large diagonal
entries and the zero off-diagonal entries in the matrix represent an uninformative prior on the
variances and no prior correlation between α and γ parameters.[54] Uniform prior distributions
(0-1) were specified for α and γ parameters.
Parameters of model (2.9) were estimated through Gibbs sampling, using Just Another
Gibbs Sampler (JAGS).[55] We ran two Markov Chain Monte Carlo (MCMC) chains. For
each chain 50,000 iterations were used to generate a posterior distribution after a 10,000 itera-
tions burn-in period. The mean estimates and 95% credible intervals (CR) were derived from
posterior distributions. For each chain, we used starting values computed from the solution of
model (2.6) using NLS. To confirm whether the model provides a reasonable fit of the data,
we plotted the observed prevalence by age with 95% confidence intervals, together with the
model-predicted prevalence.
The force of H. pylori infection, λ(a) and the average age of infection overall, A, and
among those eventually becoming infected, Ae, were estimated within the MCMC model by
evaluating Equations (2.7), (2.8) and (2.5) at each parameter set draw from the posterior dis-
tribution, respectively. We then calculated their posterior predicted mean and 95% credible
interval. All statistical modeling was conducted in JAGS [55] and R version 3.2.4 (http://www.r-
project.org).[56]
2.2.6 Model validation
To confirm the model provides a reasonable estimate of the force of infection, we compare the
model-predicted λ(a) to previous estimates of H. pylori infection incidence in 0-2 year-olds and
in 5-13 year-olds in the states of Chihuahua and Mexico City, respectively.
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2.3 Results
Table 2.1 presents the posterior summaries of the national-level α0 and γ0 parameters of the
hierarchical nonlinear Bayesian model, and the average age of infection overall, A, and for
those eventually infected, Ae. The posterior mean of the overall proportion of the population
eventually infected
(
α0
)
is 0.861 [95%CR:0.841-0.882]. The posterior mean of the overall
constant infection rate
(
γ0
)
is 0.093 [95%CR: 0.083-0.103]. We estimated an average age at
infection overall, A, of 20.5 years [95%CR: 19.0-22.0] and for those eventually infected, Ae, of
12.5 years [95%CR: 11.3-13.8].
Table 2.1: Posterior mean estimates, SD, and lower and upper bounds of the 95% credible
interval of the national-level asymptote and rate parameters of the catalytic epidemic model,
average age at infection and average age at infection of those eventually infected
Parameter Estimate SD LB UB
α0 0.861 0.010 0.841 0.882
γ0 0.093 0.005 0.083 0.103
A 20.488 0.759 19.026 22.014
Ae 12.513 0.621 11.344 13.791
Figure 2.4 shows the α and γ parameter estimates by state. Parameter estimates exhibit
substantial heterogeneity between states. More than a third of the states have posterior means
of the proportion of population eventually infected outside the 95% credible interval of the na-
tional average [95%CR: 0.841-0.881]. Six states (Baja California Sur, Coahuila, Sinaloa, San
Luis Potosi, Sonora and Mexico City) have posterior means above the upper bound of the na-
tional average while seven other states (Nayarit, Hidalgo, Tlaxcala, Tabasco, Oaxaca, Puebla
and Veracruz) have estimates below the lower bound of the national average. Half of the states
have posterior means of the infection rate parameter outside the 95% credible interval of the
estimated national average [95%CR: 0.084-0.103]. Eight states (Chiapas, Chihuahua, Guanaju-
ato, Guerrero, Baja California Sur, Tamaulipas, Queretaro and Aguascalientes) have posterior
means above the upper bound of the national average and eight other states (Michoacan, Na-
yarit, Zacatecas, Yucatan, Nuevo Leon, Hidalgo, Veracruz and Colima) have lower estimates
than the lower bound of the national average.
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Figure 2.4: State-specific posterior mean and 95% credible interval for the asymptote and rate
parameters. Solid and dashed vertical lines represent the national-level posterior mean and 95%
credible interval, respectively.
Figure 2.5 shows the observed national prevalence of H. pylori by age in Mexico, together
with the model-predicted prevalence. All but three model-predicted prevalence lie between the
95% confidence bounds of the empirical data. For one- and two-year olds the model-predicted
prevalence lies below the bounds, favoring lower prevalence than those observed for these ages.
Figure 2.6 shows the observed and model-predicted state-specific prevalence of H. pylori by age
using both the hierarchical Bayesian and the NLS models. The width of the model-predicted
credible bounds is a function of the amount of data used to estimate the state-specific prevalence.
States for which more data is available have tighter credible bounds than states with limited data.
The predicted prevalence from the NLS model are sensitive to small sample sizes overestimating
the prevalence on ages for which data are skewed towards infection. The hierarchical Bayesian
model shrinks the estimated prevalence for states with limited data towards the overall mean.
2.3.1 Force of infection
Figure 2.7 shows the model-predicted national force of infection of H. pylori by age in Mexico.
The force of infection starts at 0.08 right after birth and decreases to zero as age increases. Like
αi and γi, the state-specific force of infection varies considerably across states (Figure 2.8). At
birth, estimates of the force of infection were as high as 0.10 (Chiapas and Chihuahua) and as
low as 0.04 (Colima and Veracruz).
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Figure 2.5: Model fit to the national prevalence of H. pylori by age in Mexico in 1987-88. Gray
circles denote empirical prevalence with size proportional to sample size, and 95% confidence
interval per 1-year age group. The red solid line denotes the model-predicted posterior mean
and the red dashed lines denote the 95% credible bounds.
2.3.2 Model validation
The model-predicted force of infection is comparable with annual incidence rates of 6.56%
[95%CI: 4.6%-8.53%] in 5-8 years old and 6.01% [95% CI: 3.52% - 8.5%] in 9-13 years old
obtained by observing H. pylori incidence over time in Mexican school children who initially
tested negative for the infection.[57] Another study estimated the infection rate to be 19.84%
[95%CI: 16.43%-23.25%] from birth to two years old in a cohort of children in El Paso, Texas,
and Ciudad Juárez (Chihuahua), which is consistent with our assumption that the force of in-
fection is highest at birth and decreases with age.[58]
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Figure 2.6: Model fit to the state-specific prevalence of H. pylori by age in Mexico in 1987-
88. Gray circles denote empirical prevalence with size proportional to sample size, and 95%
confidence interval. The red solid line denotes the model-predicted posterior mean and the red
dashed lines denote the 95% credible bounds.
2.4 Discussion
In this study, we used catalytic models to estimate the force of infection of H. pylori in Mexico
at the national level, but also at the state level, accounting for state-level heterogeneity. By esti-
mating state-specific parameters simultaneously using a hierarchical nonlinear Bayesian model,
we obtained reasonable parameter estimates even for states that were sparsely sampled in a na-
tional seroprevalence survey. Sero-epidemiologic studies offer a rich source for understanding
infection dynamics, and under certain assumptions these can be used to estimate the force of
infection. Catalytic models have been previously used to estimate the force of infection of other
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Figure 2.7: Model-predicted national force of infection of H. pylori by age in Mexico in 1987-
88. The solid line denotes the model-predicted posterior mean and the dashed lines denote the
95% credible bounds.
diseases but have not previously been applied of H. pylori.
The hierarchical Bayesian approach used to estimate the catalytic model of H. pylori al-
lowed us to account for state-specific heterogeneity in the force of infection. Specifically, we
obtained better inference for under sampled states and quantified the variation across states.
We found that age-specific prevalence of H. pylori varies greatly by state. In addition,
we found great variation in the proportion of the population who eventually becomes infected
(α) and the rate of infection among those who eventually become infected (γ) across states.
These contrasting differences translate into high variation in the force of infection, which can
have implications in prevention and treatment strategies and highlights the need of state-specific
interventions.
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Figure 2.8: Model-predicted state-specific force of infection of H. pylori by age in Mexico in
1987-88. The solid line denotes the model-predicted posterior mean and the dashed lines denote
the 95% credible bounds.
Our study does have several limitations. We imposed a constrained exponential functional
form on the cumulative probability of infection, which may have overly restricted our parame-
ter estimates and the predicted force of infection. For example, the model-predicted H. pylori
prevalence consistently falls below observed prevalence for children under 2 years old, nation-
ally and for many states, which may indicate that the force of infection at these ages is being
underestimated. A more flexible catalytic model, such as a piecewise or a spline model, could
have provided a better fit to the data.[59, 60] However, by using these more flexible models we
lose the ability to link the model parameters directly to the disease process. We also assumed
that the Mexican population is in endemic equilibrium with respect to H. pylori infection, which
means that there the force of infection does not change over time. While antibiotic treatment
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for H. pylori was not widespread prior to 1991,[61, 62] this assumption could still be violated if
other factors related to H. pylori transmission, such as improved sanitation, have changed prior
to prior to 1987 (the year when NSS started collection). In addition, we assumed that disease-
related mortality is negligible compared to all-cause mortality. This would seem reasonable
in the case of H. pylori, but because it is a carcinogenic agent, there is a small fraction of the
infected population who will develop gastric cancer and face an elevated mortality risk.
Despite these limitations, we believe this work represents a proof of principal for the use of
catalytic epidemic models to estimate the force of infection of H. pylori using national seroepi-
demiologic data.
Although we found and quantified the high variation across states, we did not explain po-
tential sources for this variation. Some of these state-level explanatory variables might include
level of socioeconomic development, sanitation, education and percentage of population living
in rural areas. These factors could be used to model both the proportion of the population who
eventually becomes infected (α) and the rate of infection among those who eventually become
infected (γ). Mexico has a high sociodemographic variation in its states, so the estimated in-
fluence of state-level characteristics on the force of infection might be relevant to other Latin
American countries. This, however, is a topic of further research.
While our analysis relied on data specifically from Mexico, there are many other low-to-
middle income countries that face a similar burden of gastric cancer, where H. pylori is thought
to be the dominant cause.[63, 64, 65] Many of these countries are in Latin America and likely
have similar transmission dynamics.[1]
Application of our model to more recent sero-epidemiologic data in Mexico could help
assess if the force of infection of H. pylori has changed in time because of antibiotic treat-
ment, cohort effects or changes in other sociodemographic variables. In addition, serological
data have been employed to estimate the parameters of dynamic transmission models[66, 67]
that are then used to estimate the effectiveness and cost-effectiveness of different treatment or
vaccination strategies.[21, 68, 69] The methodology and results of this study could be used to
estimate the transmission parameters for dynamic transmission models of H. pylori to evaluate
different screen-and-treat strategies or estimate the benefits of a potential vaccine, which are
currently under development.[70, 71, 72, 73] Identifying populations at greatest risk of H. py-
lori infection will further the development of appropriately targeted prevention, screening, and
treatment strategies.
Chapter 3
Modeling the impact of antibiotic
consumption on the epidemiology of
Helicobacter pylori in the presence of
antibiotic resistance
3.1 Introduction
3.1.1 H. pylori
Helicobacter pylori (H. pylori) is one of the most prevalent chronic bacterial infections in the
world and poses a significant public health threat. The gram-negative, microaerophilic bac-
terium is commonly found in the epithelial lining of the human stomach.[41] H. pylori is a risk
factor for gastric cancer and gastric ulcers.[1, 2, 38, 39]
Once infected, the human immune response to H. pylori is often not sufficient to clear
the infection and individuals who do not receive antibiotic treatment may experience life-long
infections,[18] because spontaneous clearance is rare.[17] The global burden of disease is sub-
stantial, with H. pylori present in the stomach of half of the world’s population; however, in-
fection is much more common in developing than in developed countries. [12, 74, 75, 76] H.
pylori most heavily burdens low- and middle-income countries (LMICs) where the proportion
of people infected is approximately 70%.[42, 43]
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The mode of transmission of H. pylori remains unclear, though it appears to occur through
close personal contact, such as oral-oral or fecal-oral, particularly within the family and typi-
cally in early childhood.[1, 4, 5, 7, 8, 9, 10, 11, 13] Infection risk peaks in early childhood and
risk seems to decrease with age.[12, 16]
3.1.2 Antibiotic treatment and resistance
H. pylori infection can be cleared with antibiotics, which in theory can reduce the risk of
gastric cancer, duodenal and gastric ulcers, but previously infected individuals are at risk of
reinfection.[25, 26] Several population-wide mass treatment programs have been implemented
or proposed to eradicate H. pylori infection with the goal of reducing gastric cancer burden.[1,
36, 44, 77, 78, 79] However, no study has shown definitive evidence on reducing incidence of
gastric cancer.[80] For example, a population-based mass eradication of H. pylori infection was
undertaken in Taiwan from 2004 to 2008.[81] This program showed reductions in the incidence
of H. pylori infection, gastric atrophy and peptic ulcer disease, but the incidence and severity of
premalignant lesions such as intestinal metaplasia remained unchanged.[36] Model-based cost-
effectiveness analyses have shown that H. pylori eradication programs would be cost-effective
if they prevented at least 10% of gastric-cancer deaths and peptic ulcer disease.[82, 83, 84, 85,
86, 87]
However, the modest benefits of H. pylori mass eradication programs may be outweighed
by the development of treatment-induced antibiotic resistance (ABR), which was not accounted
for in these prior studies. Antibiotic treatment induces ABR by imposing a selective pressure for
bacteria to mutate and develop resistance while eliminating susceptible strains. An indiscrim-
inate use of antibiotics may lead to widespread ABR. Non-adherence and ABR are the main
causes of H. pylori treatment failure.[26, 27, 28, 29, 30, 31] ABR reduces the effectiveness of
treatment and represents one of the greatest emerging global health threats.[32, 33, 34] Resistant
strains of H. pylori have been identified to most antibiotics typically used to treat it, particularly
in Latin America.[35] Compared to other antibiotics, the prevalence of clarithromycin-resistant
H. pylori has been one of the most rapidly increasing in many countries over the past decade.[88]
Furthermore, the World Health Organization (WHO) recently published a priority pathogens list
that includes clarithromycin-resistant H. pylori.[89] Policies aimed at population-wide H. py-
lori eradication could have serious repercussions.[90] The impact of the increased antibiotic
consumption resulting from the mass treatment of H. pylori on H. pylori resistance is unknown
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and difficult to assess using standard study designs.
The purpose of this chapter is twofold: 1) to develop a dynamic mathematical model of the
infection and resistance of H. pylori that represents the Mexican population, and 2) to apply the
model to evaluate the impact of different antibiotic usage strategies on the prevalence of H. py-
lori infection and resistance. The mathematical model is comprised of three main components
to simulate the Mexican population over time. The first component describes the epidemio-
logic model specifying how H. pylori is transmitted from person to person as a function of age.
The second component describes the background use of antibiotics in the population over time
and the mechanism by which ABR of H. pylori arises. And finally, the third component eval-
uates different policies of targeted antibiotic use for H. pylori. This will be the first model to
comprehensively combine these components in one model.
3.2 Methods
Our transmission dynamic model has demographic, epidemiologic and resistance components.
The demographic model defines the demographic characteristics of the population being sim-
ulated and describes how persons enter, age, and exit various categories. The epidemiologic
and resistant model simulates H. pylori infection in the Mexican population over time. We
divided the population into distinct epidemiologic categories, according to the person’s status
with respect to infection, type of infection strain (i.e., sensitive or resistant) and treatment.
3.2.1 The epidemiologic model
The epidemiologic model of H. pylori in the absence of treatment can be described as a sus-
ceptible -infected (SI) model.[24, 91] In a simple SI model the population is divided into two
compartments: susceptibles (S) and infected (I).[92, 93, 94, 95] Each of these compartments
represent an epidemiologic variable as a function of time. The transmission dynamics in a
simple SI model can be described by the following system of ordinary differential equations
(ODEs)
dS
dt
= b− (βI + µ)S,
dI
dt
= βIS − µI,
(3.1)
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where susceptibles become infected at a rate βI through contact with infected individuals, new
individuals enter the population into the susceptible compartment at a rate b, and all individuals
face a mortality rate of µ. Figure 3.1 illustrates the transmission dynamics of a simple ODE SI
model.
b S I
βI
µ µ
Figure 3.1: Simplified diagram of a SI model describing the transmission dynamics of H. pylori.
To appropriately model the age-dependent dynamics of H. pylori infection, we expanded
the simple SI model to include a realistic age structure (RAS) and heterogeneous age-structured
mixing. We divided the population into n age groups and each age group, i, has its own set of
susceptible and infected compartments, Si and Ii, respectively, for i = 1 . . . , n. The RAS SI
model for H. pylori is described by the following system of 2n ODEs:
dSi
dt
= bi + di−1Si−1 − λiSi − (di + µi)Si,
dIi
dt
= di−1Ii−1 + λiSi − (di + µi)Ii,
(3.2)
which are parameterized by the age-specific force of infection (λi), aging rate (di), mortality
rate (µi), and birth rate (bi). New individuals are assumed to enter the model only through birth
into the youngest age group, so bi is defined as
bi =
 b if i = 10 otherwise (3.3)
The demographic parameters di, µi and b are calculated using the methods described in
section 3.2.3.
Force of infection
The force of infection (FOI), λ, is the key quantity governing the transmission of infection
within a given population, defined as the instantaneous per capita rate at which susceptibles
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acquire infection. FOI reflects both the degree of contact between susceptibles and infected
and the transmissibility of the pathogen per contact. Since contact is age dependent, typically
higher in children than in infants or adults, the force of infection of H. pylori is itself a function
of age [46]. In Chapter 2, we estimated the age-specific FOI of H. pylori in Mexico using a
catalytic epidemic modeling approach on a nationally representative seroepidemiology survey
conducted prior to widespread antibiotic treatment.
The age and time dependent force of H. pylori infection is defined as
λ(a, t) =
N∑
a′=1
β
(
a, a′
)
I
(
a′, t
)
, a = 1, . . . , N, (3.4)
where the transmission rate, β (a, a′), describes the probability that an infected individual of
age a′ will infect a susceptible of age a per unit of time.
The elements β (a, a′) will be estimated from the pre-antibiotic treatment force of infection
using Equation (3.4) assuming steady state, which means that FOI varies by age but does not
change over time (i.e., calendar year). That is,
λ(a, t) = λ(a) =
N∑
a′=1
β(a, a′)I(a′), a = 1, . . . , N (3.5)
To simplify notation and manipulation, we express the FOI in the following matrix notation
λ = βI
λ(1)
λ(2)
...
λ(N)
 =

β1,1 β1,2 · · · β1,N
β2,1 β2,2 · · · β2,N
...
...
. . .
...
βN,1 βN,2 · · · βN,N


I(1)
I(2)
...
I(N)
 ,
(3.6)
where βa,a′ = β (a, a′). The FOI λ(a) represents the rate of disease transmission from infected
people in all age groups to susceptibles in age group a.[96]
The standard technique to take account of mixing patterns between members of a population
based on different characteristics, such as age, is to use a Who-Acquired-Infection-From-Whom
(WAIFW) matrix. The WAIFW matrix hasN2 elements, representing mixing between each pair
of age groups in the model. The FOI in Equation (3.6) is therefore a system of N equations.
Fixing λ to the FOI estimated in Chapter 2 and I to H. pylori prevalence data, equation (3.6)
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can be solved to uniquely estimate WAIFW matrix values as long as the WAIFW structure can
be specified in terms of up to N parameters. We consider four types of mixing structures that
meet this criterion.
Who-acquires-infection-from-whom (WAIFW) matrix
The WAIFW matrix represents the effective contact rate between age groups a and a′, and the
probability of infection of an individual in age group a given a contact with an infected of age
a′. That is, each element of the WAIFW matrix is the rate at which an infected individual of age
a′ will infect a susceptible of age a per unit time. The elements of the WAIFW matrix cannot be
observed directly so they must be estimated, ideally from the FOI in the absence of antibiotic
treatment.
Data on how the population in Mexico mixes across ages are limited, therefore it is neces-
sary to assess how different mixing structures influence results. As a structural sensitivity anal-
ysis, we proposed four different WAIFW matrices with six different transmission parameters
each shown in Table 3.1. We divided the population into N = 6 discrete age classes guided by
the age groupings of the educational system in Mexico: [0, 2), [2, 6), [6, 12), [12, 19), [19, 45),
[45, 70). Notice that these age groups are coarser than are modeled in the demographic model.
The 6 × 6 WAIFW matrix represents mixing across age groups. To simplify the number of
different elements in the WAIFW matrices, we assume that interactions between age groups are
symmetric such that βa,a′ = βa′,a.
The first two WAIFW matrices,W1 andW2, represent different social mixing behaviors that
differ between age groups. The third WAIFW matrix, W3, represents similar behavior across
all age groups of infected individuals for each age group of susceptibles. The WAIFW matrix
with zeros in the off-diagonals represents a fully assortative matrix where individuals interact
with other individuals only within the same age group.
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Table 3.1: Four different WAIFW matrix structures
W1 =

β1 β1 β3 β4 β5 β6
β1 β2 β3 β4 β5 β6
β3 β3 β3 β4 β5 β6
β4 β4 β4 β4 β5 β6
β5 β5 β5 β5 β5 β6
β6 β6 β6 β6 β6 β6

, W2 =

β1 β1 β1 β4 β5 β6
β1 β2 β3 β4 β5 β6
β1 β3 β3 β4 β5 β6
β4 β4 β4 β4 β5 β6
β5 β5 β5 β5 β5 β6
β6 β6 β6 β6 β6 β6

,
W3 =

β1 β1 β1 β1 β1 β1
β2 β2 β2 β2 β2 β2
β3 β3 β3 β3 β3 β3
β4 β4 β4 β4 β4 β4
β5 β5 β5 β5 β5 β5
β6 β6 β6 β6 β6 β6

, W4 =

β1 0 0 0 0 0
0 β2 0 0 0 0
0 0 β3 0 0 0
0 0 0 β4 0 0
0 0 0 0 β5 0
0 0 0 0 0 β6

.
3.2.2 Resistance model
Resistance develops from an evolutionary perspective as a consequence of the mutation of the
bacteria in response to antibiotic therapy and of the selection pressure that provides a compet-
itive advantage for mutations that result in resistance.[97] Based on molecular studies, drug
resistance in H. pylori is predominantly due to mutations rather than the transfer of genetic
material from a resistant strain to a sensitive strain.[98, pg. 216], [99, pg. 304],[100], [101,
pg. 703] and [102, pg. 1278]. This means that resistance in H. pylori is mainly caused when
sensitive strains are exposed to antibiotics as opposed to sensitive strains picking up resistance
genes when infecting individuals harboring other resistant bacteria (due to recent past antibiotic
use, for example). If a small proportion of susceptible H. pylori bacteria develop a resistant
mutation, it will survive a course of treatment and then repopulate the stomach.[27] Therefore,
treating again with the same antibiotic will have a significant reduction in effectiveness and
H. pylori infection will persist with the possibility of spreading the resistant bacteria to other
individuals.
Studies looking at the dynamics of antibiotic resistance in H. pylori are scarce and have
been conducted mostly in non-human settings. One study estimated that mutation frequencies
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to the development of clarithromycin resistance in mice initially infected with clarithromycin-
sensitive H. pylori range from 1x10-7 to 5x10-9 per hour.[103] In humans, some insight can be
gained from a study that estimated a probability of 0.375 of sensitive strains becoming resistant
after an initial course of treatment.[104]
To represent the dynamics of ABR in H. pylori we expanded the SI model described in
section 3.2.1 into a susceptible-infected-susceptible (SIS) model[92, 94, 95, 105, 106] with
additional compartments to represent sensitive and resistant infections, and states for active
treatment.[107, 108, 109, 110] In the SIS model, individuals are born into an antibiotic-free
susceptible class
(
S0
)
. When individuals become infected, they may be colonized by either sen-
sitive (Iw) or resistant strains (Ir). Infected states are further divided into untreated
(
I0r or I
0
w
)
and treated
(
S0 or I1r
)
states, where Ir = I0r + I1r . Susceptible individuals in the absence of
treatment maybe infected by either sensitive I0w or resistant Ir bacteria.
Antibiotic treatment is applied at a rate ψp (which depends on the treatment policy) and is
assumed to clear sensitive strains with probability (1 − σ) or induce acquired resistance with
probability σ. In addition, the model allows for background use of antibiotics; which may or
may not be related to H. pylori infection but that can induce resistance,[111] at a rate α. Thus,
individuals are prescribed antibiotics at a rate α + ψp and enter either a treated susceptible
compartment S1 (from both S0 and I0w) or a treated resistant compartment I
1
r (only from I
0
w if
resistance is developed).
Generally, there are two mechanisms by which resistance can be conferred: (i) selection of
resistant mutants during treatment
(
I0w → I1r
)
, which follows the model above; and (ii) plasmid
transfer from hosts colonized with resistant strains
(
I0w → I0r
)
. Given the lack of information
for plasmid transfer in the case of H. pylori we will only consider treatment-induced resistance.
Following the introduction of antibiotic treatment for either other infections not related to
H. pylori or targeted specifically for H. pylori infection, a proportion pa = S1 + S1r are being
treated with antibiotics at all times. This model structure for representing antibiotic resistant
infections was originally proposed by Austin et al. (1997) [107] and further described in a
subsequent article.[109] The dynamics of these compartments are described by the following
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ODEs:
dS0
dt
= b−
[
βI0w + β′Ir + α+ ψp + µ
]
S0 + fI0w + γS1 + f ′I0r ,
dI0w
dt
= − [ξIr + α+ ψp + f + µ] I0w + βI0wS0,
dI0r
dt
= − [α+ ψp + f ′ + µ] I0r + β′IrS0 + ξIrI0w + γI1r ,
dS1
dt
= − [β′Ir + γ + µ]S1 + f ′I1r + (α+ ψp)S0 + (α+ ψp)(1− σ)I0w,
dI1r
dt
= − [γ + f ′ + µ] I1r + (α+ ψp)I0r + (α+ ψp)σI0w + β′IrS1,
(3.7)
where Ir = I0r + I1r and primes denote parameters for resistant strains, α is the prescribing
rate (per unit time), 1/γ the average length of treatment (typically days) and 1/f the average
duration of infection (typically months or years). In the case of H. pylori we assume that
individuals remain infected in the absence of treatment (i.e., f = 0). Resistance is assumed to be
associated with some fitness cost, which could be in the form of either reduced transmissibility
via β′ ≤ β (where β′ = φβ and φ ∈ [0, 1]) or decreased duration of infection via f ′ ≥ f , or
both. The parameter φ represents the protection provided by treatment as reduced infectivity.
Plasmid transfer is measured by the transmission parameter, ξ which is analogous to β′, equal
to the contact rate between infected multiplied by the probability that the plasmid is transferred
between infected. Typically, ξ ≤ β′. Demographics are described in more detail in section
3.2.3. Figure 3.2 describes the transmission dynamics of the SIS ODE model of ABR in H.
pylori defined in Equation (3.7).
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Figure 3.2: SIS model of antibiotic therapy and infection incorporating drug-sensitive and resis-
tant strains. Ir = I0r +I1r and primes denote parameters for resistant strains, α is the prescribing
rate (per unit time), 1/γ the average length of treatment (typically days) and 1/f the average
duration of infection (typically months or years). Antibiotic treatment is assumed to either clear
sensitive strains or induce acquired resistance with probability σ.
A key assumption of model (3.7) is that treatment is completely ineffective at clearing
resistant H. pylori strains.
In the case of H. pylori we assume that there is no fitness cost to resistance (i.e., φ = 1) and
that resistance does not occur through plasmid transfer (i.e., ξ = 0). The probability at which
infected individuals with H. pylori become resistant after an initial course of treatment, σ, equals
0.375 (95%CI: [0.04, 0.71]). This value was obtained from a study where three individuals out
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of eight total infected with H. pylori sensitive strains prior to treatment developed resistance
after treatment.[104]
The description of the variables, subscripts and superscripts of the SIS model in the presence
of ABR are shown in Table 3.2
Table 3.2: Description of variables, subscripts and superscripts
Symbol Description
Subscripts
i, j Age groups
k Treatment status (no treatment=0, treatment=1)
m Type of strain (sensitive = w, resistant = r)
p Antibiotic treatment policy
Variables
λi Force of infection at age i
Ski Susceptible with treatment status k in age group i
Ikmi Infected with type of strain m and treatment status k in age group i
Ai Antibiotic consumption
3.2.3 Parameters
The SIS model has two sets of parameters that require estimation. The first set consists of
parameters reflecting the demographic dynamics of the Mexican population (birth, death and
aging). The second set consist of the transmission parameters of the WAIFW matrices.
Demographic parameters
The demographic dynamics can be thought as independent from the infection dynamics. As
such, these can be represented through the demographic model described in Appendix A.
We estimated the demographic parameters that describe the proportion of the population in
each age group, their corresponding aging and death rates, and the rate at which new individuals
enter the youngest age group (i.e., the birth rate) using the equations shown in Appendix A.
We divided the population into yearly age groups from ages 0 to 69 and a single age group
for those aged 70 years or older. This yielded a total of 71 age groups. The death rates were
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obtained from vital statistics from Mexico’s 2012 life tables.[112] The annual growth rate q of
this demographic model was set to zero and bwas derived so that the population would be stable
in the absence of deaths from gastric cancer (Equation (A.5)). This will ensure that variation
in the results across strategies is mainly due to epidemiologic and program features rather than
peculiar characteristics of the demographic model.[113]
WAIFW matrix parameters
To estimate the six transmission parameters [β1, β2, β3, β4, β5, β6] of the WAIFW matrices, we
used a maximum likelihood estimation (MLE) approach where we assumed the FOI estimated
with the catalytic model comes from a normal distribution with mean defined by the multipli-
cation of the WAIFW matrix β and the proportion of individuals infected at each age I(a), that
is
λCM (a) ∼ Normal
(
λˆ(a), σCMa
)
,
λˆ(a) = βI(a),
(3.8)
where λCM (a) is the mean and σCMa is the standard deviation of the estimated FOI from the
catalytic model described in section 2.3.1 with data from a nationally representative survey of
H. pylori infection in Mexico.[45, 50]
All the parameters of the SIS model are described in Table 3.3.
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Table 3.3: Description of parameters
Symbol Description Value Source Range
Demographic parameters
b Birth rate; entry rate into youngest
0.014 Section 3.2.3 -
age group (i.e., newborns)
µi
Background mortality for age
age-specific [112] -
group i
di
Aging rate of age group i (i.e.,
age-specific Section 3.2.3 -
transfer rate between age groups)
li
Number of years within
[1, 30] Section 3.2.3 -
age group i
q Annual rate of population growth 0 Assumed -
Behavioral parameters
β
Vector of transmission parameters
Table 3.4 Section 3.2.3 95% CI
of WAIFW matrix
Biological parameters
φ
Protection provided by treatment
1 Assumed -
as reduced infectivity
β′
Vector of transmission parameters
β Section 3.2.3 -of WAIFW matrix on treated
individuals equal to φβ
φξ
Reduction of infectivity due to
0 Assumed -
plasmid transfer
ξ
Plasmid transfer rate, equal to the
0 Assumed -
contact rate multiplied by the
probability that the plasmid is
transferred between hosts
(typically, ξ = φξβ′ ≤ β′)
Treatment parameters
α Prescribing rate (per unit time) 0.3* [114] [0,∞)
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Description of parameters (continued)
Symbol Description Value Source Range
αi
Prescribing rate (per unit time) for
- - [0,∞)
age group i
ψpi
Antibiotic treatment policy p for
- Section 3.2.4 [0,∞)
age group i
1/γ Average length of treatment (days) 14 [115] -
σ
Probability that treatment induces
0.375† [104] [0.04, 0.71]mutation on sensitive strains and
therefore does not clear colonization
* DDDs/1000 per day
† From a study where three individuals out of eight total infected with H. pylori sensitive strains prior to treatment
developed resistance after treatment.
3.2.4 Antibiotic treatment policies
We compared three different population-wide H. pylori treatment policies: a mass treatment
strategy (AB all), where everyone in the population is treated with clarithromycin, and age-
targeted treatment strategies focusing on 2 to 6 year-old children (AB 2-6 yo) or adults aged
40 years and older (AB 40+). We also simulated a no-treatment strategy as the base case. We
assume that these mass-treatment programs are a one-time occurrence, are carried out over a
single year and only apply to persons not already on antibiotics during the year. Following the
one year intervention period, we then simulate the population (without further treatment) for X
years (analytic horizon) to estimate the impact of different one-time mass-H. pylori treatment
initiatives.[116]
3.2.5 Epidemiologic outcomes
Different antibiotic treatment policies could impact both prevalence of the disease and the preva-
lence of resistance. We assessed the epidemiologic impact of different patterns of antibiotic
usage on the total antibiotic consumption and two epidemiological outcomes by age groups
and on all the population over time: (1) prevalence of infection, and (2) prevalence of resistant
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infection.
Antibiotic consumption
We calculated the volume of antibiotics consumed under each treatment strategy in terms of
defined daily doses per 1000 adults (DDDs/1000) and is equivalent to the proportion of the
population receiving treatment at any time. The age-specific antibiotic consumption, Ai, is
given by
Ai = S1i + I1ri, (3.9)
and overall total consumption, A, is calculated as
A =
n∑
i=1
[
S1i + I1ri
]
. (3.10)
Prevalence of infection
The age-specific prevalence of infection, PIi, is given by
PIi =
∑1
k=0
∑
m∈{w,r} Ikmi∑1
k=0
(
Ski +
∑
m∈{w,r} Ikmi
) , (3.11)
where Ikmi is the proportion of the population infected with strain m, in a treatment status k and
in age group i, and Ski is the proportion of the population susceptible in a treatment status k and
in age group i.
The prevalence of infection on all the population PI is calculated as
PI =
∑n
i=1
∑1
k=0
∑
m∈{w,r} Ikmi∑n
i=1
∑1
k=0
(
Ski +
∑
m∈{w,r} Ikmi
) . (3.12)
Prevalence of resistant infection
The prevalence of resistant infection is defined as the proportion of infected individuals with a
resistant strain of all the infected population. The age-specific prevalence of resistant infection,
PIRi, is given by
PIRi =
∑1
k=0 I
k
ri∑1
k=0
∑
m∈{w,r} Ikmi
, (3.13)
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where Ikri is the proportion of the population infected with a resistant strain, in a treatment status
k and in age group i.
The prevalence of resistant infection on all the population, PIR, is given by
PIR =
∑n
i=1
∑1
k=0 I
k
ri∑n
i=1
∑1
k=0
∑
m∈{w,r} Ikmi
. (3.14)
3.2.6 Model validation
To validate the epidemiologic SI model of H. pylori infection, we compared the age-specific
observed prevalence in Mexico 1988-89 that was used to estimate the force of infection with
the model-predicted prevalence in the absence of treatment using Equation (3.11).
To validate the SIS model of antibiotic resistance for H. pylori in Mexico, we implemented
an antibiotic consumption pattern observed in the country between 1991 and 2017 and com-
pared the model results to two different observed epidemiologic outcomes in the presence of
treatment: (1) age-specific prevalence of infection, and (2) prevalence of resistant infection, de-
scribed in sections 3.2.5 and 3.2.5, respectively. For both outcomes, we simulated a population
that reflected the demographic and epidemiologic profile at 1988.
Background consumption of antibiotic
To model the background consumption of antibiotic, we considered the consumption of clar-
ithromycin. Consumption of macrolide antibiotics between 1997 and 2007 remained constant
at approximately 1 defined daily doses (DDD) per 1,000 inhabitants per day.[114, 117, 118]
Clarithromycin is a special type of macrolide antibiotic and its consumption in Mexico in 2007
was approximately 0.2 DDDs/1000 per day, which represents 20% of all macrolides. [114].
The estimated annual rate of clarithromycin consumption of 0.073/year was obtained by multi-
plying 0.2 DDDs/1000 per day times 365 divided by 1,000. Clarithromycin was introduced in
Mexico in 1991.[61, 62] To validate, the model we assumed that consumption of clarithromycin
also remained constant between 1997 and 2010. Mexico implemented a policy to enforce pro-
hibition of over the counter antibiotic sales, reduced consumption of macrolides by 5%.[118]
Accordingly, we ran the model for three years without antibiotic consumption and on 1991 we
impose an increase until 1997 and fix it at a constant level until 2010, where it is decreased by
a factor of 0.95% (i.e., the impact of over-the-counter restrictions on antibiotic consumption in
Mexico). To account for different patterns in the uptake of clarithromycin since its introduction
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in Mexico in 1991, we assumed two different increasing patterns between 1991 and 1997: (1)
linear and (2) quadratic. Figure 3.3 shows the assumed patterns of antibiotic consumption of
clarithromycin from 1997 to 2017.
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Figure 3.3: Average consumption rate of clarithromycin over time in Mexico
To account for differences in antibiotic consumption rates by age, we used a relative rate
(RR) of consumption of macrolides in the US by age groups calculated from a sample of oral
antibiotic prescriptions dispensed in the US during 2011 (see Figure 3.4).[119] To apply these
RR, we impose two assumptions: (1) the RR of consumption of macrolides is the same as that
for clarithromycin and (2) the RR in the US is a proxy of the RR in Mexico.
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Figure 3.4: Relative rate of antibiotic consumption of clarithromycin by age group
Age-specific prevalence of H. pylori infection in the presence of treatment
We compared the model-predicted age-specific prevalence of infection to the observed sero-
prevalence of the state of Morelos, Mexico in 1999 in the presence of background use of an-
tibiotic for any reason. We constructed a state-specific SIS model for the state of Morelos by
estimating four different WAIFW matrices (with the same structure of the national-level SIS
model described in section 3.2.1) using the state-specific prevalence and FOI estimated in chap-
ter 2. The observed seroprevalence was obtained from a study conducted in the state of Morelos
in 1999 in 5,299 adolescents 11-24 years old where the overall prevalence was 47.6% (95%CI:
[46.9%, 48.2%]).[120] We imposed the rate of background use of antibiotic for any reason
described in section 3.2.6 in the state of Morelos-specific SIS model. Figure 3.5 shows the
comparison of the observed seroprevalence of H. pylori infection by age among adolescents in
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the state of Morelos, Mexico in 1987–88 and 1999 with the prevalence predicted for the state
of Morelos with the catalytic model of Chapter 2.
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Figure 3.5: Comparison of observed seroprevalence of H. pylori infection by age among ado-
lescents in the state of Morelos, Mexico in 1987–88 and 1999 with the prevalence predicted for
the state of Morelos with the catalytic model of Chapter 2. Dotted lines represent the 95%CR
of the prevalence predicted by the catalytic model.
Prevalence of resistance
We compared the model-predicted prevalence of resistant infection to that observed in different
epidemiologic studies in Mexico. The prevalence of clarithromycin-resistant H. pylori in Mex-
ico in 1995, 1996 and 1997 was 10%, 21% and 26%, respectively, obtained from epidemiologic
studies in Mexico city.[35, 121]
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To account for the uncertainty of the transmission parameters, β, and the probability of
treatment-induced resistance, σ, on all validation results, we ran the model 1,000 times for
different combinations of these parameters. Different parameter combinations where drawn
from probabilistic distributions that reflect the nature of the parameters. For example, the trans-
mission parameters β were obtained from a multivariate Normal distribution with mean and
covariance matrix given by the mean estimates, standard errors and correlations shown in Table
3.4 and Figure 3.7 for the national estimates, respectively, and Table 3.5 for the Morelos-specific
estimates, all obtained from the MLE approach described in section 3.2.3. The samples for pa-
rameter σ were obtained from a Beta distribution with parameter α1 = 3 and α2 = 5 (reflecting
the 8-person sample size of the study from which σ was estimated). We then calculated the
mean and the 95% model-predicted CI of the prevalence of H. pylori infection in adolescents
by running the SIS model at each of the 1,000 parameter sets.
The ODE model was constructed in the R program version 3.2.4[56] and solved using
the function lsoda from the package deSolve.[122] The function lsoda solves ODEs by
switching automatically between stiff and non-stiff methods.[123, 124]
3.2.7 Cohort effects
Different mixing structures through WAIFW matrices might yield different direct and indirect
effects. To do so, we compared the effects of the proposed antibiotic mass-treatment policies on
the cohort of newborns and 40 year olds at the time of the policy implementation under different
WAIFW matrices. We evaluated the effects of the policies on these two cohorts by following
them until age 70 and computing the cumulative prevalence of H. pylori infection and resistance
over this period. We then compared these two outcomes for all the policies to the no-treatment
scenario.
3.3 Results
3.3.1 Estimates of WAIFW matrices and transmission parameters
We estimated the β parameters of the four different WAIFW matrices using a maximum likeli-
hood estimation (MLE) approach described in section 3.2.3. Table 3.4 shows the point estimates
and standard errors of the β parameters, and the negative log-likelihood value of each WAIFW
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matrix. The perspective plots of the four different WAIFW matrices on the point estimates from
Table 3.4 are shown in Figure 3.6. Three different WAIFW matrices, W1, W2 and W3, have the
best fit with equal negative log-likelihood values of 173.8 and thus provide no basis to guide
the choice of mixing pattern. WAIFW matrix W4 has a higher negative log-likelihood value of
321.1.
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Figure 3.6: Perspective plots of the WAIFW matrices for H. pylori infection in Mexico.
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Table 3.4: Point estimates and standard errors in parentheses of the β transmission parameters
for different WAIFW matrices for H. pylori in Mexico.
Parameter
WAIFW structure
W1 W2 W3 W4
β1 1.408 0.800 0.109 30.000
(0.209) (0.054) (0.004) (2.651)
β2 1.122 1.185 0.104 5.872
(0.150) (0.152) (0.002) (0.137)
β3 0.576 0.572 0.093 1.786
(0.023) (0.024) (0.002) (0.029)
β4 0.342 0.342 0.076 0.917
(0.007) (0.007) (0.001) (0.012)
β5 0.063 0.063 0.033 0.093
(0.001) (0.001) (0.001) (0.002)
β6 0.003 0.003 0.003 0.005
(0.000) (0.000) (0.000) (0.000)
Neg-Llk 173.821 173.821 173.821 321.097
Neg-llk: Negative log-likelihood. The lower the value the better fit.
Different WAIFW matrices can yield different correlation among their parameters. The
correlations between the β parameters of the four WAIFW matrices considered are shown in
Figure 3.7. WAIFW matrices W1 and W2 represent different social mixing behaviors that differ
between age groups of both infected and susceptible individuals, which allows correlations
different than zero for some combinations of their β parameters. The correlation between the
β parameters for these two matrices is negative. WAIFW matrices W3 and W4 do not allow
different mixing across age groups and therefore they don’t have correlation among their β
parameters.
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Figure 3.7: Correlations between the β parameters of different WAIFW matrices.
Transmission parameters for the state of Morelos, Mexico
To validate the transmission model over time on the prevalence of H. pylori infection, we com-
pared the prevalence predicted by the state-specific transmission model of Morelos to data of
prevalence of H. pylori infection in Morelos in the late 1990’s. We constructed a state-specific
model for the state of Morelos by estimating different state-specific WAIFW matrices using the
MLE approach described in Section 3.2.3 using the state-specific FOI of Morelos estimated in
Chapter 2. The point estimates and standard errors of the β parameters, and the negative log-
likelihood value of each WAIFW matrix of the state of Morelos, Mexico are shown in Table
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3.5. Two different WAIFW matrices, W2 and W3, have the best fit with equal negative log-
likelihood values of -258.3 and thus provide no basis to guide the choice of mixing pattern.
WAIFW matrix W1 had a slightly higher negative log-likelihood. WAIFW matrix, W4, had the
highest value of -242.1 providing evidence that this mixing structure is the least likely given the
data.
Table 3.5: Point estimates and standard errors in parentheses of the β transmission parameters
for different WAIFW matrices for the state of Morelos, Mexico.
Parameter
WAIFW structure
W1 W2 W3 W4
β1 1.673 0.737 0.101 30.000
(0.618) (0.159) (0.011) (7.945)
β2 0.402 1.114 0.096 5.785
(0.441) (0.445) (0.007) (0.403)
β3 0.538 0.516 0.086 1.735
(0.066) (0.067) (0.004) (0.084)
β4 0.302 0.302 0.071 0.885
(0.020) (0.020) (0.003) (0.034)
β5 0.068 0.068 0.037 0.104
(0.003) (0.003) (0.002) (0.004)
β6 0.005 0.005 0.005 0.011
(0.001) (0.001) (0.001) (0.002)
Neg-LLk -257.034 -258.270 -258.271 -242.074
Neg-llk: Negative log-likelihood. The lower the value the better fit.
3.3.2 FOI with estimated WAIFW matrices
The estimation of the WAIFW matrices impose a piecewise age-structure on transmission dy-
namics, which translates into a piecewise FOI. Therefore, we compared the piecewise FOI of
H. pylori predicted with each of the WAIFW matrices using Equation (2.1) to the continuous
FOI estimated in Mexico in 1987-88 at a national level and for the state of Morelos with the
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catalytic model in Chapter 2. The comparison between the predicted piecewise FOI from the
national WAIFW matrices to the estimated FOI is shown in Figure 3.8.
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Figure 3.8: Comparison of the piecewise FOI of H. pylori predicted with each of the national-
level WAIFW matrices using Equation (2.1) to the continuous FOI estimated in Mexico in
1987-88 with the catalytic model in Chapter 2.
The FOI predicted with the national-level WAIFW matrices W1, W2 and W3 had similar fit
to the continuous FOI estimated with the catalytic model. They all predict a decreasing pattern
on the FOI by age. The fully assortative WAIFW matrix, W4, predicts a notably lower FOI on
the youngest age group, 0-2 year-old, compared to the continuous FOI.
The comparison between the predicted piecewise FOI from the Morelos-specific WAIFW
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matrices to the estimated FOI is shown in Figure 3.9.
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Figure 3.9: Comparison of the piecewise FOI of H. pylori predicted with each of the Morelos-
specific WAIFW matrices using Equation (2.1) to the continuous FOI estimated in the state of
Morelos, Mexico in 1987-88 with the catalytic model in Chapter 2.
Similar to the national-level predicted piecewise FOI, the FOI predicted with the Morelos-
specific WAIFW matrices W1, W2 and W3 had the best fit with the equivalent age-decreasing
pattern. The fully assortative WAIFW matrix,W4, also predicts a lower FOI on the 0-2-year-old
age group compared with the estimated continuous FOI. Notice that the confidence intervals
of the continuous FOI of the state of Morelos estimated with the catalytic model are wider
compared to the national-level because the state-specific FOI are estimated with fewer data
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than the national-level FOI.
3.3.3 Validation
We ran the SI model of H. pylori infection using the WAIFW matrix W2 described in section
3.2.1. The mean and covariance of the multivariate normal distribution are given by the point
estimates and standard errors in Table 3.4 and correlation matrix of Figure 3.7, all obtained
from the MLE approach described in section 3.2.3. The age-specific prevalence of H. pylori
predicted by the SI model with their corresponding 95% predicted CI compared to the age-
specific observed prevalence of H. pylori in Mexico in 1987-88 is shown in Figure 3.10.
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Figure 3.10: Comparison of observed age-specific prevalence of H. pylori in Mexico in 1987-88
with the age-specific prevalence predicted with the SI model.
The mean prevalence of H. pylori infection and the 95% predicted CI in adolescents age 11-
24 years old with the state-specific SIS model for the state of Morelos between 1988 and 1999
compared with the observed prevalence in 1998 and 1999 of the state of Morelos, Mexico,[120]
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is shown in Figure 3.11. The model predicted prevalence in adolescents 11-24 years old for
the state of Morelos seem to mimic the observed prevalence over time. The wide confidence
intervals of the observed prevalence in Morelos in 1988 relative to 1999 is attributed to the dif-
ference in sample sizes of that state between both years. The data collected in Morelos in 1988
was part of a national representative sample while in 1999 the data was collected specifically
for that state.
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Figure 3.11: Comparison of model-predicted prevalence of H. pylori between 1988 and 1999,
and observed prevalence with 95% CI in 1988 and 1999 in the state of Morelos, Mexico in
adolescents age 11-24 years old.
The predicted prevalence of clarithromycin-resistant H. pylori in Mexico between 1988 and
1999 and the observed resistance prevalence in Mexico city between 1995-97 [121] are shown
in Figure 3.12.
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Figure 3.12: Mean and 95% model-predicted CI of prevalence of clarithromycin-resistant H.
pylori in Mexico between 1988 and 1999, and observed prevalence resistance in Mexico City.
Confidence intervals of observed resistance were computed using the Binomial exact method.
The model-predicted prevalence of resistance is lower than the observed prevalence. The
main differences occur on the years 1996 and 1997.
3.3.4 Impact of different antibiotic mass-treatment policies on epidemiologic out-
comes
In this section, we present the simulation results for the antibiotic treatment policies described
in section 3.2.4 for our base-case analysis (i.e., WAIFW matrix W2 and a quadratic uptake in
background use of antibiotic). We first simulated the population using the SIS model described
in section 3.2.2 from 1988 to 2018 considering the background use of antibiotic described in
section 3.2.6. We then implemented the one-year long antibiotic treatment policies in 2018.
50
Following the one-year intervention period, we then simulated the population (without further
treatment) for 22 years to estimate the impact of one-time population-wide treatment initiatives
on different epidemiologic outcomes.
In the absence of a mass-treatment policy, our model predicts infection begins to rise in
2022, mostly caused by treatment-induced resistant strains as a product of background use of
antibiotics. The impact of the policies is immediate on decreasing infection but also increasing
ABR (see Figure 3.13). After the first year of implementation, policy 3 (AB all) decreases
infection by 21% but increases ABR by 57%. The relative size of the decrease in infection vs.
the increase in ABR is highest for policy 2 (AB 40+ year-olds), 39%, and lowest for policy 1
(AB 2-6 year-olds), 23%. The relative size of the decrease in infection vs. the increase in ABR
for policy 3 (AB all) is 37%. These results agree across all scenarios considered in sensitivity
analysis for different WAIFW matrices and antibiotic treatment background uptake shown in
Appendix B.
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Figure 3.13: Impact of different antibiotic treatment policies on prevalence of H. pylori infection
and resistance for different antibiotic mass-treatment policies.
3.3.5 Cohort effects of different antibiotic mass-treatment policies
In this section, we compare the cohort effects of different antibiotic mass-treatment policies for
all the WAIFW matrices described in section 3.2.1. We computed the cumulative prevalence of
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H. pylori infection and resistance for a cohort born in 2018 (i.e., the year when the policies are
implemented) over 70 years. For all the policies, WAIFW matrices W1 and W2 have similar
effects. WAIFW matrix W3 consistently estimates the lowest prevalence of H. pylori infection
and resistance while W4 estimates the highest values for both epidemiologic outcomes (see
Figures 3.14 and 3.15).
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Figure 3.14: Cohort effects of different antibiotic mass-treatment policies on prevalence of H.
pylori infection.
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Figure 3.15: Cohort effects of different antibiotic mass-treatment policies on prevalence of
resistance.
3.4 Discussion
In this chapter, we developed an integrated transmission dynamic model of H. pylori infection
and resistance to represent the Mexican population. We estimated the transmission parameters
of different mixing matrices based on different structures of how the population mixes across
age. We validated the model by comparing model-predicted age-specific and aggregated preva-
lence of H. pylori infection in steady state and over time, respectively, to observed prevalence
from different studies. In addition, we also compared the model-predicted prevalence of resis-
tant infection to that observed in Mexico City in the mid 1990’s. We then used this model to
evaluate different antibiotic mass-treatment policies on several epidemiologic outcomes such as
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prevalence of infection and resistance.
We gained valuable insights by comparing various antibiotic mass-treatment strategies. In
general, the results suggest that any mass-treatment policy will have a higher effect on increas-
ing resistance than on reducing infection. In fact, as the proportion of H. pylori resistant strains
increases and becomes more prevalent than sensitive strains, H. pylori infection starts rising
again.
Most validation results from this model were qualitatively similar to the observed epidemi-
ologic outcomes on the age-specific and aggregated prevalence of H. pylori infection and preva-
lence ore resistance. However, we were not able to validate the model-predicted prevalence of
resistance to data in more recent years due to the lack of recent studies that report prevalence
of resistance to clarithromycin in Mexico. Thus, we had to predict current levels of resistance
in Mexico (60%) before simulating the antibiotic mass-treatment policies in 2018. Model-
predicted levels of resistance seem higher compared to published estimates for Mexico,[35]
although most of these studies were conducted more than a decade ago. However, our predicted
prevalence of resistance for more recent years is not far off from other studies reporting high lev-
els of resistance in similar years.[125] For example, in Iran, a study reported a resistance to clar-
ithromycin of 45.2% [95%CI: 38.3%-52.2%] on 197 individuals in 2009.[126] A larger study
in Southeast China from 2010 to 2012 found that H. pylori resistance to clarithromycin was
21.5% [95%CI: 20.9%-22.1%].[127] Another study conducted in 71 children in Beijing, China,
from 2009 to 2010 found a much higher clarithromycin resistance of 84.9% [95%CI: 76.7%-
93.3%].[128] In addition, our model-predicted prevalence of resistance over time in more recent
years is in line with resistance in other countries, such as in South Korea where resistance in-
creased from 22.9% [95%CI: 13.1%-32.9%] in 2003 to 37.0% [95%CI: 29.6%-44.4%] in 2012
[129], and in Japan where H. pylori resistance went from 1.8% [95%CI: 0.0%-3.8%] in 1996 to
27.1% [95%CI: 21.2%-33.0%] in 2008.[130] These studies provide evidence on the quick rise
of clarithromycin resistance in the last few years.
Our current analysis has several limitations. First, there is limited data on the background
use of clarithromycin in Mexico over time. Therefore, we had to make assumptions on the
uptake of clarithromycin since its introduction to the Mexican health care sector in 1991; al-
though different assumptions on the antibiotic uptake did not change the results. Second, data
on treatment-induced resistance for H. pylori infection are also limited, with only one study
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reporting the probability of clarithromycin-induced resistance. Uncertainty around this param-
eter has a big effect on the predicted prevalence of resistance over time, as shown in Figure
3.12. Thus, more studies are needed to more accurately estimate antibiotic-treatment-induced
mutation rate. Third, the assumption of mixing of the population has differential cohort effects.
Different WAIFW matrices predict different levels of infection and resistance across a lifetime
for different mass-treatment policies. Therefore, care should be taken when choosing the mix-
ing structure across age of the population of interest. More accurate data on how the Mexican
population mixes across age would help refining our current results.
Mass-treatment policies have a higher effect on increasing ABR letting resistant strains
take over infection. Given the high predicted prevalence of ABR at the time of the policy
implementation, mass treatment strategies are unlikely to be optimal in Mexico.
Chapter 4
Cost-effectiveness analysis of
population screening and treatment of
Helicobacter pylori in the setting of
antibiotic resistance
4.1 Introduction
Gastric cancer is the fourth most common type of cancer and the second cause of cancer death
globally. Latin America has the second highest rate of gastric cancer mortality in the world.
In particular, in Mexico gastric cancer is the third highest cause of cancer death in adults, with
some regions having cancer mortality rates that are twice the national average (8.0 vs. 3.9 per
100,000, respectively).[3]
Helicobacter pylori (H. pylori) is the strongest known biological risk factor for gastric can-
cer (about a six-fold increase of risk compared to H. pylori negative individuals) and causes
the majority of peptic ulcers.[2, 1] In 2008, more than 79% of the 989,000 gastric cancer cases
and most ulcer cases in the world could be attributed to chronic infection with H. pylori.[2] H.
pylori is one of the most prevalent chronic bacterial infections in the world and most heavily
burdens low- and middle-income countries (LMICs) where the proportion of people infected
is approximately 70%. The current understanding is that H. pylori causes gastritis and chronic
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inflammation, which significantly increases the risk of developing an ulcer, followed by atro-
phy of the gastric glands leading to precancerous lesions, and ultimately resulting in gastric
cancer.[131]
H. pylori infection can be cleared with antibiotics, and in theory reduce the risk of gastric
cancer and peptic ulcers.[25, 26] However, antibiotic treatment can result in antibiotic resistance
(ABR), which is the natural response of bacteria to resist the threats designed to eliminate
them. ABR is one of the main causes of H. pylori treatment failure [27] and represents one of
the greatest emerging global health threats.[32, 33] H. pylori has developed resistance to most
antibiotics typically used to treat it,[132] including in the Latin American region.[35]
Given the high burden of H. pylori infection in the population, a policy of antibiotic-based
mass eradication in developing regions has been proposed, and even implemented in targeted
high-risk populations.[36] However, the adverse consequences of mass use of antibiotics, such
as ABR, might outweigh the benefits. It is crucial to investigate this issue further in order to
choose the best policy to treat H. pylori infection.[1] Therefore, it is important to only treat
appropriate cases with selected regimens based on the observed patterns of ABR in the target
population.[1] Failing to do so may lead to overtreatment and increase of ABR, especially in
developing countries where prevalence of H. pylori infection is high. Current guidelines for
North America and other western countries, do not suggest universal treatment for H. pylori
but rather to those who may benefit from treatment; the key task is to determine who these
individuals are, which is an important contribution of this research.[26, 133] However, there are
recommendations to intervene to prevent gastric cancer in subpopulations with high background
rates of H. pylori in western countries.[134, 135]
Under a “screen-and-treat” approach, asymptomatic individuals (i.e., individuals with out
symptoms of having the disease of interest) are subjected to a screening test and treatment
decision is based on the test result, which should be provided soon or, ideally, immediately after
a positive screening test.[37] The goal of a screen-and-treat approach for H. pylori infection
is to reduce gastric malignancies and cancer, and related mortality with relatively few adverse
effects, such as ABR. The screen-and-treat approach for H. pylori infection must include a
screening test or strategy (sequence of tests) and be linked to appropriate treatments for H.
pylori infection.[136] There are several test for H. pylori infection that could be either invasive
or noninvasive. Invasive tests are done via endoscopy and include culture, histology, rapid
urease testing (RUT) and polymerase chain reaction (PCR).[137] For screening, noninvasive
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tests are preferred, such as urea breath test (UBT), stool antigen and serology.[137, 138, 139,
140, 141, 142]
Efforts to combat resistance in the treatment of H. pylori focus on the development of new
combinations of drugs, but few focus on optimizing use of existing antibiotics.[27] Screen-
ing policies of early detection of H. pylori have proven cost-effective, but most have failed
to consider both the broader benefits in terms of reduction of the infection in the population,
as well as the adverse effects of widespread use of antibiotics, such as resistance.[82] There-
fore, the design of H. pylori screen-and-treat strategies must fit the narrow criteria to be an
acceptable compromise between cancer prevention aims [143] and infection prevention, with
the containment of ABR.[1, 144] Therefore, the design of H. pylori screen-and-treat strategies
must, fit the narrow criteria to be an acceptable compromise between cancer prevention aims
(cost-effectiveness)[143] and infection prevention (mass eradication reduces sources of infec-
tion), with the containment of ABR. [1, 144]
Susceptibility to different antibiotics can be assessed using a susceptibility test, which
improves prediction on antibiotic treatment outcomes and guide clinicians in their choice of
therapy.[145] In the case for H. pylori infection, there are basically two different susceptibility
testing methods: (1) phenotypic methods and (2) genotypic methods.[99] Phenotypic meth-
ods include agar dilution method (usually considered the gold-standard to compare other tech-
niques) and Etest.[137] Genotypic detection of resistance includes the real-time PCR method.
[146]
Recent recommendations from the Maastricht IV Consensus Report on diagnosing H. pylori
infection, suggest that culture and antibiotic susceptibility testing should be performed if pri-
mary resistance to clarithromycin is higher than 20% in a given geographical area or after failure
of second-line treatment.[26] Although this recommendation explicitly mentions a threshold of
resistance to recommend susceptibility testing, there is no evidence on whether the 20% thresh-
old is appropriate. Other recommendations mention that treatment with clarithromycin is re-
stricted to geographical areas with low prevalence of resistance without mention of any specific
threshold.[147] Susceptibility testing could be considered as part of a screening strategy, but
there is lack of evidence on its effectiveness and cost-effectiveness.
Epidemiological models of infectious diseases are mathematical representations of the dy-
namics and subsequent disease progression. These models are widely used for many con-
ditions including human immunodeficiency virus (HIV),[148] human papillomavirus (HPV)
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[149, 150, 151, 152] and hepatitis C [153, 154, 155], and provide information about the under-
lying mechanisms that influence the spread of disease and may suggest control strategies.[156]
Current models of H. pylori do not incorporate transmission dynamics, effects of antibiotic
treatment and ABR in one single model.[91, 24] Previous analyses that have evaluated benefits
of treatment have used either decision trees [157, 158] or Markov models that simulate fixed co-
horts without accounting for transmission between the population, background use of antibiotic
and ABR.[83, 159, 86] Previous transmission models of H. pylori have evaluated the benefits
and cost-effectiveness of potential vaccines but have not evaluated mass antibiotic treatment or
screen-and-treat strategies.[160, 161]
The purpose of this paper is to directly inform the design and implementation of public
health interventions and clinical practice to prevent gastric cancer in a population with a high
prevalence of H. pylori infection where ABR is present. In addition, we explore the potential
benefits in different settings such as prevalence of infection, mutation rates and background use
of antibiotics. We estimated the cost-effectiveness of various screen-and-treat strategies for H.
pylori infection and ABR in the Mexican population from the health sector perspective.[85, 87]
We considered different testing strategies including those used to identify ABR strains.[162,
163]
4.2 Methods
4.2.1 Mathematical model
We developed a mathematical model to simulate the Mexican population over time to replicate
outcomes in Mexico. The mathematical model consists of several components, such as H. pylori
infection, ABR, and gastric disease dynamics. The first and second components described in
Chapter 3 model the transmission dynamics of H. pylori infection and ABR at a population
level using an epidemiologic model of H. pylori. The third component described in section
4.2.1 below, describes the progression of underlying gastric disease following Correa’s natural
history model of gastric carcinogenesis including gastritis, intestinal metaplasia, dysplasia and
ultimately cardia gastric cancer (NCGC).[131, 164, 165, 166, 167, 168]
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Susceptible-infected-susceptible model with antibiotic resistance
We expanded the system of ordinary differential equations (ODEs) of the susceptible-infected-
susceptible (SIS) model described in Chapter 3 to account for each gastric disease state g de-
scribed in Section 4.1 above and different screen-and-treat strategies. The transmission dynam-
ics of H. pylori infection have been described in more detail in Chapter 3. Briefly, individuals
are born into an antibiotic-free susceptible class with normal mucosa
(
S0N
)
and infected individ-
uals may be colonized by either sensitive
(
I0wg
)
or resistant strains (Irg). Furthermore, (Irg)
is divided into untreated-resistant
(
I0rg
)
and treated-resistant
(
I1rg
)
, where Irg = I0rg + I1rg.
Susceptible individuals in the absence of treatment, S0g , may be infected by either sensitive I
0
wg
or resistant bacteria Irg. Antibiotic treatment is assumed to either clear sensitive strains with
probability (1 − σ) or induce acquired resistance with probability σ. Once accounting for all
age groups, infected and gastric disease states, the system of ODEs had 2,130 equations.
We implemented screen-and-treat strategies on the SIS model by adding a screening rate η
that gets applied to individuals in all gastric disease states g that are currently not being treated
for H. pylori S0g , I
0
wg and I
0
rg. We assumed that screening is performed using an imperfect test
with sensitivity ρ and specificity θ. In addition, we also incorporated a susceptibility test with
sensitivityρs and specificity θs.In section 4.2.3 we describe in more detail the screen-and-treat
strategies. Figure 4.1 shows the diagram of the SIS model accounting for ABR and screen-and-
treat strategies for each gastric disease state g.
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Figure 4.1: SIS model of screen-and-treat with antibiotic therapy incorporating drug-sensitive
and resistant strains for each gastric disease state g ∈ {N,G,A,M,D,NCGC}. Primes de-
note parameters for resistant strains. Parameters in red refer to screening parameters and those
in blue refer to susceptibility test.
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Gastric disease dynamics
To accurately quantify the effects of screen-and-treat strategies for H. pylori infection it is im-
portant to model the effect of H. pylori infection on the natural history of gastric cancer. H. py-
lori causes gastritis and chronic inflammation, followed by atrophy of the gastric glands leading
to leading to precancerous lesions such as intestinal metaplasia and dysplasia, ultimately lead-
ing to gastric cancer.[18, 164, 165, 169, 170] Gastritis is an inflammation of the gastric mucosa
without causing serious complications.[131, 171] Chronic atrophic gastritis is characterized by
the ‘loss of appropriate glands’, mostly of parietal and principal cells that drive a reduction
in the secretion of peptic acid and increases the risk of developing gastric cancer.[167, 172].
Intestinal metaplasia is considered a pre-cancerous lesion, which is usually caused by chronic
H. pylori infection and is considered as a condition that predisposes to malignancy.[172, 173]
Gastric dysplasia is defined as intraepithelial or intraglandular neoplasia and is considered as
the immediate precursor to gastric cancer.[167]
The population in steady state is distributed across six different health states that include
a normal gastric mucosa (N) state and five gastric precancerous states, which include, non-
atrophic gastritis (G), atrophic gastritis (A), intestinal metaplasia (M), and intestinal dysplasia
(D). New individuals are born into a normal gastric mucosa (N) state at an annual rate b (same
rate calculated in Chapter 3). Furthermore, individuals residing in one state face a transition
rate to either progress or regress to a consecutive state. For example, individuals with atrophic
gastritis can either regress to non-atrophic gastritis at a rate λAG, progress to intestinal meta-
plasia at a rate λAM or remain with atrophic gastritis. Individuals who develop dysplasia face
a rate λNCGC of developing non-cardia gastric cancer. The dynamics of precancerous gastric
disease are shown in Figure 4.2.
Progression transition rates λNG and λGA (depicted with dashed lines) are higher for H.
pylori infected individuals (i.e., hazard ratio (HR) greater than 1). Treatment for H. pylori
influences these transitions but not those in solid lines.[174] That is, once individuals develop
intestinal metaplasia, it is considered a point of no return.[173, 175]
The simulated population face an age-specific mortality from other causes according to
country-specific life tables. We assumed that neither H. pylori infection nor any precancerous
condition increases a person’s age-specific mortality.
There are limited individual level data to estimate the progression and regression rates of the
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Figure 4.2: Diagram of gastric disease dynamics
natural history model of gastric cancer in Mexico. Therefore, we used a model calibration ap-
proach to estimate the parameters of the natural history model of gastric cancer using available
epidemiologic data. In section 4.2.2 below, we describe in more detail the calibration approach
we used to estimate these parameters.
4.2.2 Calibration of gastric disease dynamics
Parameters of mathematical models could be either unobserved or unobservable due to differ-
ent reasons (e.g., financial, practical or ethical). Model calibration is the process of estimating
values for unknown or uncertain parameters of a mathematical model by matching model out-
puts to observed clinical or epidemiological data (known as calibration targets). The goal is
to identify parameter values that maximize the fit between model outputs and the calibration
targets.[176, 177, 178]
Current guidelines suggest that model calibration should be performed where there are ex-
isting data on outputs.[179] And more importantly, uncertainty around calibrated parameters
should be reported and reflected in both deterministic and probabilistic sensitivity analysis.[180]
There are several calibration techniques but not all of them are able to fully reveal both the
uncertainty and correlation among the input parameters. Bayesian methods are naturally suited
for calibration because they reveal the posterior joint and marginal distributions of the input
parameters.[54, 181] A posterior distribution from a Bayesian analysis is synonymous with the
distribution of the calibrated parameters.[182, 183]
In its simplest form, Bayes’ theorem is defined as
p(θ|y) = l(y|θ)p(θ)
p(y) , (4.1)
where θ is a set of unknown parameters of the mathematical and y is the observed target data.
The posterior distribution p(θ|y) is the conditional probability of the parameters after observing
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y. The prior distribution p(θ) represents the uncertainty of θ before observing any target data.
p(θ) could be a vague distribution represented by a uniform distribution where all the values
are equally likely within a pre-specified range. Alternatively, p(θ) can have certain values more
likely than others that could be represented by a normal distribution, for example. The likeli-
hood function l(y|θ) represents the data generation mechanism of the targets y and is usually
represented by either a probability density function (pdf) if y are continuous or a probability
mass function (pmf) if y are discrete.
Because the denominator is not a function of θ, we can rewrite Equation (4.1) as
p(θ|y) ∝ l(y|θ)p(θ), (4.2)
which means that the posterior distribution is equal up to a proportional constant to the prior
times the likelihood.
In the context of model calibration, Y ∼ f(y;φ), where f denotes a either a probability
density function (pdf) if y are continuous or a probability mass function (pmf) if y are discrete,
φ are the model outputs, which in turn depend on θ. Given that y is observed, the likelihood
function can be defined as l(y|θ) = f(y;φ). The posterior distribution p(θ|y), represents the
updated distribution of θ after the model fits the target data y. Notice that this is equivalent
to the definition of a calibrated parameter because it represents the updated distribution of that
parameter after we incorporate the observed data. Thus, Bayes’ formula can be viewed as defin-
ing a calibrated parameter as a function of the prior parameter distributions and the simulation
model.
Each term in Equation (4.2) could be translated to a component in a calibration framework.
Table 4.1 relates each term in Bayes’ theorem with its counterpart in a calibration process.
That is, Bayes theorem is naturally suited for calibration as it produces the distribution of the
parameters accounting for previous knowledge about them and the targets of interest.
Table 4.1: Contrasting Bayes theorem with a calibration process.
Term Bayesian Context Calibration Context
p(θ) Prior distribution of θ Pre-calibrated parameters
l(y|θ) Likelihood of the data given θ Goodness-of-fit for a parameter set
p(θ|y) Posterior distribution of θ given targets y Calibrated model parameters
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There are multiple methods to obtain the posterior distribution . Some of them could be
computationally expensive such as a Markov chain Monte Carlo (MCMC) method that simu-
lates the posterior distribution by jumping (i.e., sampling) the parameter space in a stochastic
fashion. MCMC techniques require a high number of model runs in order for the algorithm to
converge.[183] Other approaches use importance sampling, such as the sampling-importance-
resampling (SIR) algorithm [184] or an improved version that combines sequential importance
sampling with optimization methods called incremental-mixture importance sampling (IMIS),
developed specifically for mechanistic models.[185]
To calibrate the progression and regression rates of the gastric disease natural history model
described in section 4.2.1, we used a different calibration Bayesian approach that aims to iden-
tify the parameter set that maximizes the posterior parameter distribution. Specifically, we
adopted a Laplace approximation where we computed the posterior mode often called the max-
imum a posteriori (MAP) point, by maximizing the logarithm of the posterior, and use the MAP
point (instead of the mean) as an approximation of the parameter set θ. The inverse of the neg-
ative Hessian of the logarithm of the posterior can be used to measure the uncertainty of this
approximation.[186, 187, 188, 189, 190]
Because the population model has a constant inflow of individuals -–at a birth rate b— that
then age, we initialize the model at a defined distribution of the population across all age groups,
infection and treatment status, and gastric disease sates. We then identify the parameters that
maintain this distribution in steady state. To solve for the steady state of the gastric disease
natural history model, we used the function runsteady from R package rootSolve. The
function runsteady solves the steady-state condition of ODEs by dynamically running till the
summed absolute values of the derivatives become smaller than some predefined tolerance.[191,
192]
Calibration targets
We used data from different epidemiologic and population studies as calibration targets, such
as the prevalence of total gastritis (i.e., a combination of both chronic non-atrophic and atrophic
gastritis), the proportions of gastric lesions by age and H. pylori infection status, and the age-
specific gastric cancer incidence. At the time of this study, we could not find studies that report
the prevalence of gastritis by age for the Mexican population. Therefore, we had to use data
65
from a different country. Specifically, we used data from a Finnish study that reported preva-
lence of total gastritis by age groups.[193] We used data for Mexico on the proportion of gastric
lesions and gastric cancer incidence.
Prevalence of gastritis The prevalence of total gastritis (i.e., a combination of both chronic
non-atrophic and atrophic gastritis) by age groups was obtained from biopsy samples from∼500
consecutive endoscopy Finnish outpatients in the late 80s (Jorvi hospital, Espoo, Finland).[193]
These data might be an underrepresentation of the prevalence of total gastritis in Mexico be-
cause the prevalence of H. pylori in Finland has been consistently lower compared to Mexico,
particularly in the lower age groups.[194, 195] Figure 4.3 shows the prevalence increases with
age.
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Figure 4.3: Prevalence of gastric lesions by age
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Proportion of gastric lesions The proportion of the population with each of the gastric lesions
by age group came from study conducted in patients who consulted because of gastroduodenal
symptoms or because of a probable gastric cancer, programmed for endoscopy and biopsy for
diagnostic purposes in two oncology hospitals in Mexico City from 1999 to 2002.[196] Table
4.2 shows the number of patients with different gastric lesions by age group and H. pylori status.
Table 4.2: Gastric lesions by age and H. pylori status for a sample of patients in Mexico in
1999-2002.
H. pylori
Age(y)
Lesion
status Non–atrophic Atrophic Intestinal
Dysplasia
gastritis gastritis metaplasia
Negative
30-44 40 0 5 0
45-54 27 2 2 0
55-64 17 0 5 0
65+ 14 0 7 1
Positive
30-44 131 1 14 0
45-54 71 6 21 0
55-64 39 2 25 0
65+ 29 3 31 1
The proportion of the population with each gastric lesion by age group and H. pylori status
with their corresponding 95% CI is shown in Figure 4.4. We estimated the 95%CI using the
Sison-Graz method assuming proportions of gastric lesions within each age group and H. pylori
status follow a multinomial distribution.[197, 198] We used the R package MultinomialCI
to compute these 95% CI.[199]
gastric cancer incidence Age-specific gastric cancer incidence estimates for Mexico came
from GLOBOCAN 2012.[200, 201, 202] The rate, cases, standard errors and 95% CI are shown
in Table 4.3. We estimated the 95% CI using an exact method assuming cancer cases within
each age group follow a Poisson distribution. We used the R package epitools to compute
these 95% CI.[203]
Figure 4.5 shows cancer incidence by age group with their corresponding 95% CI.
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Figure 4.4: Proportion of gastric lesions by age and H. pylori status for a sample in Mexico in
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Likelihood functions
We assigned a likelihood function to each type of target. To compute an aggregated likelihood
measure across all targets, we added the log-likelihoods of each target. For the proportion of
gastric lesions by age, we assumed that the number of individuals with a gastric lesion g for age
group i, Ngi with g ∈ {G,A,M,D} follow a multinomial distribution
[NGi, NAi, NMi, NDi] ∼ Multinomial (Ni; [pGi, pAi, pMi, pDi]) , (4.3)
where Ni is the total number of individuals in age group i and pgi is the model predicted-
proportion of individuals with gastric lesion g for age group i.
To compute the likelihood for cancer incidence and prevalence of gastritis for age group i,
we assumed that they follow a normal distribution. For example, let gastric cancer incidence
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Table 4.3: Gastric cancer incidence in Mexico in 2012 by age group with corresponding stan-
dard errors (SE), and 95% CI lower bounds (LB) and upper bounds (UB). Rates per 100,000
Age group Rate Cases SE LB UB
15-39 1.10 509 0.05 1.01 1.20
40-44 5.00 394 0.25 4.52 5.52
45-49 8.20 537 0.35 7.52 8.92
50-54 12.30 688 0.47 11.40 13.25
55-59 17.60 815 0.62 16.41 18.85
60-64 25.10 856 0.86 23.45 26.84
65-69 35.80 914 1.18 33.52 38.20
70+ 58.31 2964 1.07 56.23 60.44
and prevalence of total gastritis for age group i be denoted by yi:
yi ∼ Normal (φi, σi) , (4.4)
where φi is the model predicted-incidence and σi is the standard error of the target for age group
i.
Prior distributions
All the parameters that need to be calibrated are defined over positive numbers. Thus, we
assumed that their prior distributions follow a log-normal distribution. The ranges given in
Table 4.6 are assumed to represent the 95% equal-tailed interval for a log-normal distribution.
Steady state distribution of the population
The demographic and infection steady state distributions are detailed in Chapter 3. For the
distribution of the population in each gastric disease state, we estimated the proportion of the
population with each gastric lesion for ages 0-70 by fitting a multinomial logistic regression
[204] on an expanded dataset based on the aggregated data for the proportion of gastric lesions
in Mexico shown in Table 4.2 and Figure 4.4. Briefly, we expanded the aggregated data by
generating repeated observations by the number of individuals with each gastric lesion k =
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Figure 4.5: Gastric cancer incidence in Mexico in 2012 by age group with confidence intervals,
and crude and age-standardized rates (ASR).
0, . . . , 3, H. pylori infection status and age group, and assigned them the median age for each
age group. For example, for the 131 individuals in Table 2 in the category with non-atrophic
gastritis, positive H. pylori infection in age group 30-44, we created 131 identical observations
with non-atrophic gastritis, positive H. pylori infection and age 37. We then modeled each
gastric lesion k with independent binary logistic regression models as a function of age and H.
pylori status, in which non-atrophic gastritis, k = 0, is chosen as the reference category. The
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other three categories are separately regressed against the reference category. That is,
ln Pr (Yi = 1)
Pr (Yi = 0)
= β1Xi,
ln Pr (Yi = 2)
Pr (Yi = 0)
= β2Xi,
ln Pr (Yi = 3)
Pr (Yi = 0)
= β3Xi,
(4.5)
where Yi = k represents individual i has gastric lesion k, βk is a vector of coefficients including
the intercept andXi is a vector of covariates for individual i, such as age and H. pylori infection
status.
We estimated the coefficients of the multinomial model in Equation (4.5) using the function
vglm of the package VGAM via maximum likelihood (ML).[205] We then predicted the pro-
portion of each gastric lesion by H. pylori status and for ages 0 to 70 years, Pˆ r (Yage,Hp = k),
using the following expression
Pˆ r (Yage,Hp = 0) =
1
1 +∑3k=0 eβˆkX ,
Pˆ r (Yage,Hp = 1) =
eβˆ1X
1 +∑3k=0 eβˆkX ,
Pˆ r (Yage,Hp = 2) =
eβˆ2X
1 +∑3k=0 eβˆkX ,
Pˆ r (Yage,Hp = 3) =
eβˆ3X
1 +∑3k=0 eβˆkX ,
(4.6)
where βˆk is the estimated vector of coefficients for gastric lesion k and X is the design matrix
with the values of interest of age and H. pylori infection status.
The estimated parameters of the multinomial model described in Equation (4.5) are shown
in Table 4.4.
The trend in growth of the predicted proportions of gastric lesions by age does not vary by
H. pylori infection status. Non-atrophic gastritis declines with age and the rest of gastric lesions
increase with age. Intestinal metaplasia has the highest increase and dysplasia has the lowest
increase. The predicted and observed proportions of all gastric lesions by age and H. pylori
status are shown in Figure 4.6.
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Table 4.4: Estimated coefficients of the multinomial model.
Coefficient Estimate Std. Error z value Pr(>|z|)
β01 -6.448 1.444 -4.464 0.000
β02 -5.210 0.610 -8.542 0.000
β03 -108.735 5080.855 -0.021 0.983
βAge1 0.049 0.022 2.174 0.030
βAge2 0.066 0.010 6.861 0.000
βAge3 1.517 72.584 0.021 0.983
βHp1 0.850 0.777 1.094 0.274
βHp2 0.650 0.293 2.216 0.027
βHp3 -0.789 1.442 -0.547 0.584
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Figure 4.6: Predicted proportion of gastric lesions by age and H. pylori status with 95% CI error
bands from a sample of patients in Mexico in 1999-2002.
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The rate of growth of gastric lesions by age varies by H. pylori infection status. The decrease
in non-atrophic gastritis is more pronounced in patients H. pylori-positive patients compared to
H. pylori-negative patients. In both atrophic gastritis and intestinal metaplasia, the increase is
higher in H. pylori-positive patients compared to H. pylori-negative patients. The increase in
dysplasia by age is higher in H. pylori-negative patients compared to H. pylori-positive patients.
The difference in predicted gastric lesions by H. pylori infection status is shown in Figure 4.7.
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Figure 4.7: Difference in predicted proportion of gastric lesions by age and H. pylori status with
95% CI error bands from a sample of patients in Mexico in 1999-2002.
For the distribution of the population in at least one gastric lesion state, we estimated the
prevalence of the population with total gastritis for ages 0-70 by fitting a linear regression on
the aggregated data shown in Figure 4.3. That is, we modeled the prevalence of total gastritis
for age group i denoted by yi with a linear regression model as a function of age:
yi = b0 + b1xi + i, (4.7)
where b0 is the intercept, b1 is the coefficient representing the effect of age on the prevalence
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of total gastritis, xi is the median age in age group i, and i is the error term. We estimated
the coefficients of the linear model in Equation 4.7 using ordinary least squares (OLS). We then
predicted the prevalence of total gastritis for ages 0 to 70 years using the following expression
yˆ = bˆ0 + bˆ1x, (4.8)
where x = 0, . . . , 70.
4.2.3 Screen-and-treat algorithms
We implemented different screen-and-treat strategies with two different testing algorithms: (1)
test only for H. pylori infection and treat if positive (SnT), and (2) test for H. pylori infection and
if positive, test for susceptibility and if test indicates susceptibility to clarithromycin, treat with
clarithromycin; otherwise, treat with second line treatment (SnT-ST). We assume that screening
will only be implemented in the population currently not getting any antibiotics (i.e., S0g , I
0
wg
and I0rg).
For the screening test, we considered the urea breath test (UBT). UBT is a popular and
accurate noninvasive test for diagnosis of H. pylori infection and can be safely used in children
and women of childbearing age.[137] We used the test characteristics of UBT from a recent
meta-analysis with a pooled sensitivity of 96% (95%CI: 0.95-0.97) and a pooled specificity of
93% (95%CI: 0.91-0.94).[140]
The susceptibility test actually tests for both susceptibility and H. pylori infection status,
but it requires a biopsy, which is why we do not consider using it as a single test. To detect for
susceptibility to clarithromycin, we used the GenoType HelicoDR assay, which is a molecular
test that combines polymerase chain reaction (PCR) and hybridization, allowing the molecu-
lar identification of H. pylori as well as clarithromycin resistance within 6 hours. In previous
studies, the GenoType HelicoDR assay using bacterial strains or gastric biopsy specimens was
highly accurate for clarithromycin resistance with 94%-100% sensitivity and 86%-99% speci-
ficity respectively.[137, 206, 207, 208] We assumed that testing for infection using a suscepti-
bility test has a sensitivity of 100% and specificity of 90%, based on the test characteristics of
culture.[209]
For the second line treatment, we assume an effectiveness of 0.80 based on recent reports
of effectiveness of Bismuth-containing quadruple therapy (PPI, bismuth, tetracycline, metron-
idazole) after failure of clarithromycin-based therapy.[210] These screening algorithms will be
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applied to the simulated population at a rate η.
4.2.4 Screen-and-treat policies
We implemented six different population-wide H. pylori screen-and-treat policies, three for
each of the two testing algorithms described in section 4.2.1. We also simulated a do-nothing
strategy (i.e., non H. pylori screening or treatment) to have a common comparator in the absence
of any policy. The different screen-and-treat policies evaluated are:
• Policy 1: No screen-and-treat (No SnT)
• Policy 2: Screen-and-treat 2-6 year olds (SnT 2-6 yo)
• Policy 3: Screen-and-treat 40+ year olds (SnT 40+)
• Policy 4: Screen-and-treat all the population (SnT all)
• Policy 5: Screen-and-treat with susceptibility test 2-6 year olds (SnT-ST 2-6 yo)
• Policy 6: Screen-and-treat with susceptibility test 40+ year olds (SnT-ST 40+)
• Policy 7: Screen-and-treat with susceptibility test all the population (SnT-ST all)
We assume these policies are implemented in 2018 and are carried out over 13 years (i.e.,
implementation period). Individuals who are not receiving antibiotics during the year are as-
sumed to be screened each year. Following the introduction of the screen-and-treat policies,
we then simulate the population for 70 years (i.e., analytic horizon, T ) to capture the long-term
impact of these policies.[116] Note that for 57 years (i.e., 70-13) the impact of the policies will
be quantified following the implementation period.
4.2.5 Variables and Parameters
The variables, subscripts and superscripts of the mathematical model are described in Table 4.5.
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Table 4.5: Description of variables, subscripts and superscripts
Symbol Description
Subscripts
i, j Age groups
g Gastric disease state (N,G,A,M,D,NCGC)
k Treatment status (no treatment=0, treatment=1)
m Type of strain (sensitive = w, resistant = r)
p Antibiotic treatment policy
Variables
λi Force of infection at age i
Skgi Susceptible with gastric lesion g and treatment status k in age group i
Ikmgi Infected with type of strain m, gastric lesion g and treatment status k in
age group i
Ai Antibiotic consumption
The parameters of the different components of the mathematical model, such as the gastric
disease dynamics, screening and treatment, and the cost-effectiveness analysis are shown in
Table 4.6.
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Table 4.6: Description of parameters
Symbol Description Value Source Range
Gastric Disease Dynamics
Transition rates (annual)
λNG Normal Mucosa
0.0052
Calibrated
[0.001, 0.01]
to non-atrophic gastritis Section 4.2.2
λGA Non-atrophic gastritis
0.0043
Calibrated
[0.001, 0.01]
to atrophic gastritis Section 4.2.2
λAM Atrophic gastritis
0.0300
Calibrated
[0.001, 0.05]
to intestinal metaplasia Section 4.2.2
λMD Intestinal metaplasia
0.0002
Calibrated
[0.001, 0.01]
to dysplasia Section 4.2.2
λNCGC Dysplasia
0.0054
Calibrated
[0.001, 0.01]
to gastric cancer Section 4.2.2
λGN Non-atrophic gastritis
0.0032
Calibrated
[0.001, 0.01]
to normal mucosa Section 4.2.2
λAG Atrophic gastritis
0.0018
Calibrated
[0.001, 0.01]
to non-atrophic gastritis Section 4.2.2
λMA Intestinal metaplasia
0.0018
Calibrated
[0.001, 0.01]
to atrophic gastritis Section 4.2.2
λDM Dysplasia
0.0021
Calibrated
[0.001, 0.01]
to intestinal metaplasia Section 4.2.2
µNCGC Gastric cancer mortality rate 0.3238 [211] [0.023, 0.033]
Hazard ratios
HRNG Normal mucosa
5.2
Calibrated
[1, 5]
to non-atrophic gastritis Section 4.2.2
HRGA Non-atrophic gastritis
1.9
Calibrated
[1, 15]
to atrophic gastritis Section 4.2.2
HRAM Atrophic gastritis
1.0
Assumed
[1, 5]
to intestinal metaplasia Section 4.2.2
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Description of parameters (continued)
Symbol Description Value Source Range
Screening parameters
η Screening rate (per unit time) 1 Assumed –
ηi
Screening rate (per unit time) for
1 Assumed –
age group i
ρ Sensitivity of screening UBT 0.96 [140] [0.95, 0.97]
θ Specificity of screening UBT 0.93 [140] [0.91, 0.94]
ω Susceptibility test 0–1 Assumed –
ρs
Sensitivity of susceptibility test
1.00 [209] –
to identify infection
θs
Specificity of susceptibility test
0.90 [209] –
to identify infection
ρsr
Sensitivity of susceptibility test
0.97 [137, 206, 207] [0.94, 1.00]
to identify resistance
θsr
Specificity of susceptibility test
0.93 [137, 206, 207] [0.86, 0.99]
to identify resistance
Treatment parameters
α Prescribing rate (per unit time) 0.3* [114] –
αi
Prescribing rate (per unit time) for
– – –
age group i
ψpi
Antibiotic treatment policy p for
– Section 3.2.4 –
age group i
1/γ Average length of treatment (days) 14 [115] -
σ
Probability that treatment induces
0.375† [104] [0.04, 0.71]mutation on sensitive strains and
therefore does not clear colonization
h Effectiveness of 2nd line treatment 0.80 [210] [0.70, 0.92)
Cost-effectiveness parameters
Costs (MXN$)‡
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Description of parameters (continued)
Symbol Description Value Source Range
cHpRx Cost of H. pylori treatment $780 [212] –
cDx Cost of screening test of H. pylori $165 [213] –
csDx Cost of susceptibility test $252 [213] –
cGC Cost of gastric cancer treatment $66,303 [212] –
Health utilities
uN Utility for normal 0.95 [214] [0.94, 0.96]
uG Utility for non-atrophic gastritis 0.79 [215] [0.77, 0.81]
uA Utility for atrophic gastritis 0.79 [215] [0.77, 0.81]
uM Utility for intestinal metaplasia 0.79 [215] [0.77, 0.81]
uD Utility for dysplasia 0.79 [215] [0.77, 0.81]
uNCGC Utility for NCGC 0.68 [215] [0.55, 0.81]
Discount factors (annual)
δc Discount factor for costs 3% [216] [3%, 7%]
δe Discount factor for effectiveness 3% [216] [3%, 7%]
* DDDs/1000 per day
† From a study where three individuals out of eight total infected with H. pylori sensitive strains prior to treatment
developed resistance after treatment.
‡ In 2015 Mexican pesos (MXN$).
4.2.6 Epidemiologic impact of screen-and-treat strategies
To assess the epidemiologic impact of each screen-and-treat strategy we use two main outcome
measures of effectiveness: life years (LY) and quality-adjusted life years (QALYs).
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Years of life
The total number of undiscounted and discounted years spent alive by the active population,
LY and LY d, respectively, under strategy x given by
LYx =
T∫
0
( 71∑
i=1
Ni
)
dt, (4.9)
LY dx =
T∫
0
e−δet
( 71∑
i=1
Ni
)
dt, (4.10)
whereNi is the size of the population in age group i, δe is the discount rate for effectiveness and
T is the analytic horizon. All the parameters and state variables are described in more detail in
Table 4.6
Quality-adjusted life years
The second outcome considers the quality of life weight associated to different health states
into a QALY. Let ug be the utility assigned to spend one year in a gastric disease state g, where
g ∈ {N,G,A,M,D,NCGC}. The undiscounted and discounted QALYs under strategy x
over the analytic horizon, T , are given by
QALYx =
T∫
0
 6∑
g=1
71∑
i=1
ugNgi
 dt, (4.11)
QALY dx =
T∫
0
e−δet
 6∑
g=1
71∑
i=1
ugNgi
 dt, (4.12)
where Ngi is the size of the population in gastric disease state g and age group i calculated as
Ngi = S0gi + S1gi + I0wgi + I0rgi + I1rgi. (4.13)
All the parameters and state variables are described in more detail in Table 4.6
Estimates of health utilities
There are no health utility estimates for the Mexican population for either the general popu-
lation or any of the gastric disease sates. Therefore, we used health utility estimates for these
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health states from other populations. For the normal gastric mucosa states, we used a health
utility uN of 0.95 from the general population obtained from recently published article that es-
timated health utilities for the Uruguayan population.[214] We used the same health utility for
all asymptomatic precancerous gastric lesions of 0.79 (i.e., uG = uA = uM = uD = 0.79)),
obtained from a multicenter study of gastric premalignant conditions and malignant lesions in
Portugal.[215] This study used the EQ-5D-5L questionnaire developed by the EuroQol Group,
which is a standardized measure to provide utilities for clinical and economic appraisal.[217]
The health utilities ere estimated by converting the responses to the EQ-5D-5L questionnaire by
setting preferences for the general population using the time trade-off technique. The estimate
of the health utility associated to gastric cancer uNCGC of 0.68 was also obtained from this
study.[215]
4.2.7 Costs of screen-and-treat strategies
Screening costs
The cost of screening per unit time is the product of the cost per screening test cDx, the screening
rate ηi per unit time (e.g., every year), and the size of the population eligible for screening∑71
i=1
{
S0i + I0wi + I0ri
}
. For simplicity, we assumed that the population under treatment will
not be eligible for screening. Thus, the total screening costs associated with strategy x at time t
are
Screenx(t) = cDx
 6∑
g=1
71∑
i=1
ηi
{
S0gi + I0gwi + I0gri
} . (4.14)
Susceptibility test costs
The cost of susceptibility testing per unit time is the product of the cost per susceptibility test
csDx, the screening rate ηi per unit time (e.g., every year), and the size of the population as-
signed to receive the susceptibility test, which are those with a positive screening test result∑71
i=1
{
(1− θ)ωS0gi + ρω
[
I0gwi + I0gri
]}
. Thus, the total susceptibility test costs associated
with strategy x at time t are
SusTestx(t) = csDx
 6∑
g=1
71∑
i=1
ηi
{
(1− θ)ωS0gi + ρω
[
I0gwi + I0gri
]} . (4.15)
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Costs of H. pylori antibiotic treatment
Treatment costs of H. pylori are the product of the population on the treated states and the cost
of treatment cHpRx. Thus, the total treatment costs of strategy x at time t are
Treatx(t) = cHpRx
 6∑
g=1
71∑
i=1
{
S1gi + I1gri
} . (4.16)
Costs of gastric cancer treatment
Treatment costs of gastric cancer are the product of the population in the gastric cancer disease
state (i.e., g = 6) across all infection status and the cost of gastric cancer treatment cGC . Thus,
the total treatment costs of gastric cancer of strategy x at time t are
CancerTreatx(t) = cGC
( 71∑
i=1
{
S06i + S16i + I06wi + I06ri + I16ri
})
. (4.17)
Note that people with precancerous lesions are assumed to remain asymptomatic; therefore,
they are never identified nor treated.
Total costs
The discounted total cost of strategy x over the planning horizon, T , is
Costx =
T∫
0
e−δct (Screenx(t) + SusTestx(t) + Treatx(t) + CancerTreatx(t)) dt,
(4.18)
where δc is the discount rate for costs.
Incremental cost-effectiveness ratio
To compare mutually exclusive non-dominated screen-and-treat strategies we first calculated
the incremental cost-effectiveness ratio (ICER) by taking the difference in discounted total costs
and divide it by the difference in discounted total QALYs of strategy x and its next best strategy
x′,
ICERx,x′ =
Costx − Costx′
QALY dx −QALY dx′
. (4.19)
82
Second, we identified the strategies on the cost-effectiveness frontier using an efficient non-
iterative algorithm [218] and finally, selected the optimal strategy with the highest ICER that
falls at or below the threshold willingness to pay (WTP) for additional QALY.[216]
4.2.8 Methodological assumptions
We adopted a health care sector perspective. Other methodological assumptions used in the
cost-effectiveness analysis followed the updated recommendations by the Second Panel on
Cost-Effectiveness in Health and Medicine.[216] In particular, we adopted a discount rate of
3% for both costs and health effects on a lifetime time horizon. Costs are expressed in 2015
Mexican pesos (MXN$). In Mexico, an intervention is considered to be cost-effective if the
ICER is less than or equal to 1-times GDP per capita.[219, 220] Mexico’s GDP per capita for
2013 was MXN$132,000.[221]
4.3 Results
4.3.1 Model fit
The calibrated parameters are shown in Table 4.6. Figures 4.8, 4.9 and 4.10 depict the model
output for the prevalence of total gastritis, proportions of gastric lesions and cancer incidence
using the MAP estimate in comparison to the observed target data. The majority of model-
predicted outputs from the MAP estimate fell within the 95% confidence intervals of the target
data.
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Figure 4.8: Observed and model-predicted prevalence of gastritis using MAP estimate.
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Figure 4.10: Observed and model-predicted gastric cancer incidence using MAP estimate for
the population in Mexico.
4.3.2 Cost-effectiveness analysis
Under base-case assumptions, the model predicts that from the health care payer’s perspective,
the screen-and-treat strategy with susceptibility test on children 2-6 year-olds (SnT-ST 2-6 yo)
and the entire population (SnT-ST all) cost MXN$2,277 and MXN$7,796 per QALY gained,
respectively (Table 4.7). Thus, taking MXN$132,000 per QALY gained as upper limit for an
intervention to be considered cost-effective, screening and treating the entire population with a
susceptibility test would be worthwhile from the health care payer’s perspective.
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Table 4.7: Cost-effectiveness analysis of screen-and-treat strategies for H. pylori infection in the
setting of antibiotic resistance. D: strongly dominated strategy; d: weakly dominated strategy.
Strategy
Costs Effectiveness ∆ C ∆ Eff ICER
(MXN$) (QALYs) (MXN$) (QALYs)
(MXN$/
QALYs)
Policy 1 (no screening) 126 14.4999 0 0 -
Policy 2 (screening 2-6 yo) 208 14.5000 82 0.0001 700,447
Policy 3 (screening 40+ yo) 699 14.5005 - - d
Policy 4 (screening all) 1,352 14.5014 1,144 0.0014 792,773
All screening policies produced higher effectiveness compared to a no-screen-and-no-treat
policy. This means that regardless of the current predicted level of resistance, screening and
treating for H. pylori infection will produce epidemiologic benefits at a population level. How-
ever, all policies were costlier than the do-nothing strategy. Policies including susceptibility
test were more effective but also costed more than their counterparts without susceptibility test.
In the case of policy 5 and policy 7, the additional benefits obtained with susceptibility test
outweighed the additional costs. Figure 4.11 shows the cost-effectiveness plane with the cost-
effectiveness efficiency frontier (represented by the solid line). Policies that lie on the frontier
are considered the set of potentially cost-effective strategies. In our analysis, we found that
when considered no SnT as the comparator, only two policies lie on the frontier: SnT-ST 2-6
yo and SnT-ST all.
4.4 Discussion
In this chapter, we expanded an integrated transmission dynamic model of H. pylori infection
and resistance to simulate gastric disease dynamics of the Mexican population by incorporating
multiple pre-cancerous gastric lesions and gastric cancer. We calibrated the parameters govern-
ing the natural history of gastric disease using a Bayesian approach that allowed us to weight
the relevance of the targets based on their uncertainty using a likelihood function. In addition,
we overlaid two different screening algorithms for H. pylori in which one accounts for suscep-
tibility testing. Our model incorporates the known epidemiologic and economic consequences
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resulting from different screen-and-treat policies such as life years and QALYs, and costs of
screening and treating for H. pylori and treating for gastric cancer. We used both costs and
QALYs to compute the cost-effectiveness of such policies.
Currently, clinical guidelines do not recommend screening and treating for H. pylori in
asymptomatic individuals.[26] Our results suggest that there appear to be H. pylori screen-
ing and treatment strategies that would be considered cost-effective in Mexico. Using a cost-
effectiveness threshold of the GDP per capita (MXN$132,000 in Mexico), we found screening
and treating for H. pylori all the population would be considered cost-effective.
Our cost-effectiveness results are similar to other CEAs that found that screening and treat-
ing for H. pylori is cost-effective. However, given the high levels of resistance, screening for
H. pylori has to be done with susceptibility tests. We acknowledge that conducting suscepti-
bility tests could be costly and require medical equipment that is not readily available in most
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of Mexico and that our results represent a scenario where technology to conduct biopsies and
susceptibility tests does not require additional investment of infrastructure. Accounting for the
need of investing in medical technology to conduct susceptibility testing will likely increase
the ICER by making the policies costlier in terms of MEX$/QALYs gained. However, the
investment would only occur once while the returns would be carried over a long period. In
addition, an investment in technology to test for clarithromycin resistance will have direct spill-
over effects such as being able to perform biopsies for reasons other than H. pylori infection
and susceptibility testing, and will to test for resistance for other antibiotics with high resistance
like metronidazole.
Our current analysis has several limitations. First, we do not account for non-adherence of
treatment, which is also an important determinant of treatment failure.[26, 27, 28, 29, 30, 31]
Therefore, our current analyses and results represent the maximum possible benefit. That is,
by considering non-adherence the benefits of treatment could decrease. Second, we assumed
the test characteristics of UBT and susceptibility testing does not vary across all ages. There
is evidence that at least UBT can vary by age. Specifically, UBT test is less accurate in
young children, but adjusting cutoff value, pretest meal, and urea dose, this accuracy can be
improved.[222] Third, screening costs only include cost of screening and susceptibility tests
but did not include any additional labor cost or cost of scaling up current infrastructure to meet
demands of proposed policies. Fourth, we did not allow for the possibility of second line treat-
ment to become resistant. Therefore, our results represent the maximum effectiveness of adding
a second line treatment with less than perfect effectiveness. Fifth, we assumed that the preva-
lence of total gastritis using Finnish data was generalizable to Mexico. This is most likely not
the case given that prevalence of H. pylori in Finland is notoriously lower than in Mexico; there-
fore, prevalence of total gastritis in Finland represents an under estimation or this prevalence in
Mexico. Unfortunately, there are no available data either for the country or the region regarding
these epidemiologic outcomes. Sixth, we assumed that the proportion of gastric lesions by age
from the study conducted in Mexico City was generalizable to the whole Mexican population.
Compared to another study conducted in Colombia in the 1980’s,[223] our estimates of the pro-
portion of atrophic gastritis in Mexico are significantly lower than those from Colombia and
our estimates of intestinal metaplasia are significantly higher than the Colombian. This could
have an effect on the calibrated parameters because the order between these two gastric lesions
is reversed between countries. In addition, there is high variation of gastric cancer incidence
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across Mexican states, which could also represent geographical variation in the proportion of
gastric lesions. Therefore, a larger study to estimate the proportion of gastric lesions in Mexico
could potentially benefit the calibration of the natural history model presented in this chapter.
And lastly, we assumed that H. pylori infection increases the risk of non-atrophic and atrophic
gastritis only. However, H. pylori may also promote progression to more advanced precancer-
ous lesions. In such cases, our model-predicted benefits of antibiotic treatment for H. pylori
infection represent a conservative estimate because we are not allowing for a reduction on the
progression rates to more advanced gastric lesions from clearing H. pylori infection.
In summary, the results from this model suggest that in a setting of H. pylori screening,
screening and treating with susceptibility test the entire population can substantially improve
quality of life and be cost-effective. Model-based policy analyses using a decision-analytic
framework allow for exploratory analyses of the potential health and economic outcomes of
different screen-and-treat strategies of H. pylori infection for the prevention of gastric lesions
and gastric cancer.
Chapter 5
Conclusion and discussion
This thesis investigates various aspects of the dynamics of H. pylori infection and ABR, and
the impact of mass-treatment and screen-and-treat strategies on epidemiologic and economic
outcomes in Mexico.
In Chapter 2, we used catalytic models to estimate the force of infection of H. pylori in
Mexico at the national level, but also at the state level, accounting for state-level heterogeneity.
By estimating state-specific parameters simultaneously using a hierarchical nonlinear Bayesian
model, we obtained reasonable parameter estimates even for states that were sparsely sampled
in a national seroprevalence survey. We found that age-specific prevalence of H. pylori varies
greatly by state, which translates into high variation in the force of infection, which can have
implications in prevention and treatment strategies and highlights the need of state-specific
interventions. Seroepidemiologic studies offer a rich source for understanding infection dy-
namics, and under certain assumptions these can be used to estimate the force of infection.
Catalytic models have been previously used to estimate the force of infection of other diseases
but have not previously been applied to H. pyloriO˙ur work represents a proof of principal for the
use of catalytic epidemic models to estimate the force of infection of H. pylori using national
seroepidemiologic data.
In Chapter 3, we developed an integrated transmission dynamic model of H. pylori infection
and resistance to represent the Mexican population. We estimated the transmission parameters
of different mixing matrices based on different structures of how the population mixes across
age. We validated the model by comparing model-predicted age-specific and aggregated preva-
lence of H. pylori infection in steady state and over time, respectively, to observed prevalence
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from different studies. We then used this model to evaluate different antibiotic mass-treatment
policies on several epidemiologic outcomes such as prevalence of infection and resistance.
In general, the results suggest that any mass-treatment policy will have a higher effect on
increasing resistance than on reducing infection. In fact, as the proportion of H. pylori resistant
strains increases and becomes more prevalent than sensitive strains, H. pylori infection starts
rising again. Given the high predicted prevalence of ABR at the time of the policy implementa-
tion, mass treatment strategies are unlikely to be optimal in Mexico.
In Chapter 4, we expanded an integrated transmission dynamic model of H. pylori infection
and resistance to simulate gastric disease dynamics of the Mexican population by incorporating
multiple pre-cancerous gastric lesions and gastric cancer. We calibrated the parameters govern-
ing the natural history of gastric disease using a Bayesian approach that allowed us to weight
the relevance of the targets based on their uncertainty using a likelihood function. In addition,
we overlaid two different screening algorithms for H. pylori in which one accounts for suscepti-
bility testing. We then used this model to evaluate different screen-and-treat policies on several
epidemiologic and economic outcomes such as life years and QALYs, and costs of screening
and treating for H. pylori and treating for gastric cancer. We incorporated both costs and QALYs
to compute the cost-effectiveness of such policies. Using a cost-effectiveness threshold of the
GDP per capita (MXN$132,000 in Mexico), we found screening and treating for H. pylori all
the population would be considered cost-effective.
5.1 Implications
Introducing screen-and-treat strategies for H. pylori infection in Mexico may have important
implications. A screening test will decrease the number of individuals exposed to H. pylori
infection-targeted antibiotic, which will reduce the rate of treatment induced-resistance com-
pared to treating the entire population. In addition, screening with an additional susceptibility
test can optimize current lines of treatment by prescribing the right course of antibiotic treatment
to infected individuals that who would truly benefit from it.
Because these strategies offer substantial public health impact, clinical studies to evaluate
the long-term consequences of screening for H. pylori infection, treating infected individuals
based on their susceptibility to the antibiotic and the impact of these treatments on overall
resistance should be given the highest priority.
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5.2 Future work
In this thesis, we simulated the whole Mexican population on the transmission model without
accounting for any differences across states. Given the high variation of infection and gastric
cancer mortality across geographical states in Mexico, state-specific transmission models could
provide guidance on the optimal policy for each of state based on their state-specific infection
dynamics. In Chapter 2, we estimated state-specific force of infection, which could be directly
used to construct these state-specific transmission models, like the one we constructed for the
state of Morelos on Chapter 3 for validation purposes.
In addition, some of the estimates are highly uncertain because they were either obtained
from few studies with small sample sizes or obtained from different populations. This could
have immediate consequences if different but equally good fitting parameters yield different
recommendations. We plan to address this issue in future studies by conducting a value of infor-
mation analysis (VOI) on key parameters with high uncertainty, such as the antibiotic treatment-
induced mutation rate, assumptions on the different dynamics of resistance and natural history
of gastric disease, and the background use on antibiotics. VOI is used to determine whether
future research should be conducted based on the expected cost of uncertainty surrounding a
decision with current information. VOI analysis is a quantification of the importance of reduc-
ing parameter uncertainty and avoiding the consequences of sub-optimal decisions.[224, 225]
5.3 Summary
In summary, using a simulation model-based policy analyses under a decision-analytic frame-
work we found that given the high predicted prevalence of ABR at the time of the policy imple-
mentation, mass treatment strategies and screening without susceptibility test are unlikely to be
optimal in Mexico. Screening and treating for H. pylori could be cost-effective. However, given
the high levels of resistance, screening for H. pylori has to be done with susceptibility tests.
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Appendix A
Demographic model
A.1 Demographic model structure
The demographic model consists of a population that is divided into a finite number of n age
groups defined by the age intervals [ai−1, ai], where 0 = a0 < a1 < a2 < · · · < an−1 < an =
∞, that moves across different age groups at aging rates di and face age-related causes of death
rates di. All the symbols used to describe variables and parameters are defined in Tables 3.2
and 3.3.
Assuming that the population distribution has reached a steady state with exponential growth
or decay of the form eqt, Hethcote [95] provides a system of n ordinary differential equations
(ODEs) for the sizes of the n age groups. In this formulation the maximum age is not explicitly
defined because we assume that the last interval includes all the individuals over age an−1.[92,
p. 267] and [95, p. 623]. Let A(a) be the age-distribution function, and assume that it is
piecewise constant, with a value in [0, 1) for each year of age. Let Pi be the proportion of the
population with ages in [ai−1, ai]. Then Pi is given by [95, p. 623]:
Pi =
∫ ai
ai−1
A(a) da (A.1)
In this case the age distribution is not explicitly calculated from data, but determined from
the population’s life tables. We assume that there is negligible population growth (population
growth is denoted by q; this assumption can be relaxed by allowing q to be nonzero) and that
the population has reached an equilibrium age distribution. Using [95, Equation 4.11, p. 624],
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the proportion in the youngest age group is
P1 =
(
1 +
n∑
i=2
di−1
(di + µi)
)−1
, (A.2)
and the proportions in the following groups are
Pi =
di−1Pi−1
di + µi
, i = 2, . . . , n. (A.3)
For a multi-year age group, we take the mean of the rates. The aging rates are modified by
the death rates, so that
di =
µi + q
exp[(µi + q)li]− 1 , (A.4)
where li is the number of years in the i-th age group.
In this manuscript the birth rate b refers to the rate at which individuals enter the youngest
age group (i.e. newborns) it is defined as
b = (d1 + µ1 + q)P1. (A.5)
Using Equations (A.2), (A.3), (A.4) and (A.5) the dynamics of the population can be de-
scribed by the following system of n ordincary differential equations (ODE) [95, p. 623]:
dP1
dt
= b− (d1 + µ1)P1,
...
dPi
dt
= di−1Pi−1 − (di + µi)Pi,
...
dPn
dt
= dn−1Pn−1 − (µn + dn)Pn,
(A.6)
where the population at each age group ai either transfer to an older age group at age-specific
rate di (equal to zero for the oldest age group) or die at rate µi.
Appendix B
Additional Figures
Care has been taken in this thesis to minimize the excess use of figures in the main text, but this
cannot always be achieved. This appendix includes figures of additional analysis conducted in
this thesis.
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B.1 H. pylori SIS model in the setting of antibiotic resistance
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Figure B.1: Impact of different antibiotic treatment policies on prevalence of H. pylori infection
and resistance for different antibiotic mass-treatment policies under different WAIFW matrices
and background antibiotic uptakes.
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B.2 Cost-effectiveness analysis of population screening and treat-
ment of H. pylori in the setting of antibiotic resistance
Figure B.2: Screen and treat algorithm for individuals in all infectious disease states
Appendix C
Glossary and Acronyms
Care has been taken in this thesis to minimize the use of jargon and acronyms, but this cannot
always be achieved. This appendix defines jargon terms in a glossary, and contains a table of
acronyms and their meaning.
C.1 Glossary
• Cost-effectiveness analysis (CEA) is a form of economic evaluation that quantifies the
health benefits and costs of interventions designed to improve the health of a population.
[216]
• Cost-effectiveness acceptability curves (CEAC) is a graphical representation of the
probability that interventions are cost-effective at different cost-effectiveness thresholds.
[226, 227]
• Cost-effectiveness acceptability frontier (CEAF) indicates the probability of being
cost-effective for the strategy with the highest expected net benefit.[228]
• Confidence interval (CI) is an interval in which a measurement or trial falls correspond-
ing to a given probability.
• Catalytic epidemic model (CM) Catalytic epidemic models are concerned with the age
by which individuals are or have been infected. For an age-dependent catalytic epidemic
model it is assumed that the force of infection λ(a) acts upon members of a susceptible
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population of age a. Such would be the case if exposure to infection, the level of transmis-
sibility remains constant in time and if infection were endemic in the population.[46, 48]
• Credible interval (CR) is an interval on the posterior probability distribution that in-
cludes a given probability.
• Defined daily doses (DDD) “Sales or prescription data presented in DDDs per 1000
inhabitants per day may provide a rough estimate of the proportion of the study population
treated daily with a particular drug or group of drugs. As an example, the figure 10
DDDs per 1000 inhabitants per day indicates that 1% of the population on average might
receive a certain drug or group of drugs daily. This estimate is most useful for chronically
used drugs when there is good agreement between the average prescribed daily dose (see
below) and the DDD. It may also be important to consider the size of the population used
as the denominator. Usually the general utilization is calculated for the total population
including all age groups, but some drug groups have very limited use among people
below the age of 45 years. To correct for differences in utilization due to differing age
structures between countries, simple age adjustments can be made by using the number
of inhabitants in the relevant age group as the denominator.” [229] ATC/DDD Index 2017
• Deterministic sensitivity analysis (DSA) involves varying a parameter or set of param-
eters from their base-case values and reporting the implications for the results.[216]
• Force of infection (FOI) is the instantaneous rate at which susceptible individuals ac-
quire infection.
• Gastric cancer (GC) is cancer developing from the lining of the stomach.[230]
• Helicobacter pylori (H. pylori) "is a spiral-shaped bacterium that grows in the mucus
layer that coats the inside of the human stomach." [231]
• Hazard ratio (HR) is the ratio of the hazard rates.
• Incremental cost-effectiveness ratio (ICER) is calculated by taking the difference in
discounted total costs and divide it by the difference in discounted total QALYs of strategy
x and its next best strategy x′.[216]
• Life years (LY) represent the number of years that a population or an individual lives.
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• Minimal inhibitory concentration (MIC) – Is the lowest concentration of antibiotic
that inhibits the growth of a bacterium. Reports typically contain a quantitative result in
µg/mL and a qualitative interpretation. The interpretation usually categorizes each result
as susceptible (S), intermediate (I), resistant (R), sensitive-dose dependent (SD), or no
interpretation (NI)
• Non-cardia gastric cancer (NCGC) – Gastric cancer on the distal region.
• Ordinary differential equation (ODE) is a differential equation containing one or more
functions of one independent variable and its derivatives.
• Probabilistic sensitivity analysis (PSA) is a method used to represent parameter uncer-
tainty. In a PSA all parameters that are uncertain are varied simultaneously, with multi-
ple sets of parameter values being sampled from priori–defined probability distributions.
[180]
• Quality-adjusted life years (QALY) – A generic measure of disease burden, including
both the quality and length of life.[216]
• Relative rate (RR) – A RR is a ratio of two different rates.
• Susceptible-infected (SI) epidemiologic model – A SI model represents the dynamics of
interactions between susceptible and infected individuals to model the rate of emergence
of new infectious individuals.[232]
• Susceptible-infected-susceptible (SIS) epidemiologic model – A model for a disease
from which infected individuals recover with no immunity.[232]
• Value of information (VOI) – The value of acquiring more precise information about
uncertain parameters of a decision model.[224]
• Who-acquires-infection-from-whom (WAIFW) matrix – Represents the effective con-
tact rate between age groups (i.e. the rate at which an infective of age a′ will infect a
susceptible of age a). Contains the values of the transmission rates between groups: the
element in the i-th row and j-th column denotes the probability that an infective in the
j-th group will infect a susceptible in the i-th group per unit time.
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• The World Health Organization (WHO)
– A specialized agency of the United Nations that is concerned with international public health.
C.2 Acronyms
Table C.1: Acronyms
Acronym Meaning
CEA Cost-effectiveness analysis
CEAC Cost-effectiveness acceptability curves
CEAF Cost-effectiveness acceptability frontier
CI Confidence interval
CM Catalytic epidemic model
CR Credible interval
DDD Defined daily doses
DSA Deterministic sensitivity analysis
FOI Force of infection
GC Gastric cancer
H. pylori Helicobacter pylori
HR Hazard ratio
ICER Incremental cost-effectiveness ratio
LY Life years
MIC Minimal inhibitory concentration
NCGC Non-cardia gastric cancer
ODE Ordinary differential equation
PSA Probabilistic sensitivity analysis
QALY Quality-adjusted life years
RR Relative Rate
SI Susceptible-infected
SIS Susceptible-infected-susceptible
Continued on next page
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Table C.1 – continued from previous page
Acronym Meaning
VOI Value of information
WAIFW Who-acquires-infection-from-whom matrix
WHO The World Health Organization
